

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number  
**WO 01/31020 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/31**,  
C07K 7/06, 14/21, A61K 47/48, 38/00

**David, J.** [US/US]; 1202 Azalea Drive, Rockville, MD 20850 (US). **IADAROLA, Michael, J.** [US/US]; 3500 Rodman Street, N.W., Washington, DC 20008 (US).

(21) International Application Number: PCT/US00/29064

(22) International Filing Date: 20 October 2000 (20.10.2000)

(74) Agents: **LOCKYER, Jean, M.** et al.; Townsend And Townsend And Crew LLP, Two Embarcadero Center, 8th floor, San Francisco, CA 94111-3834 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/161,159 22 October 1999 (22.10.1999) US

(71) Applicant (for all designated States except US): **THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, as represented by **THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; Bethesda, MD 20892 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.




(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(72) Inventors; and  
(75) Inventors/Applicants (for US only): **FITZGERALD,**

(54) Title: **DISULFIDE CONJUGATED CELL TOXINS AND METHODS OF MAKING AND USING THEM**

(57) Abstract: The invention pertains to the discovery of novel disulfide linked cell toxins which can ablate NK-1 receptor expressing cells. These toxins are used as pharmaceutical compositions for the ablation of NK1 receptor expressing cells and comprise a substance P (SP)-*Pseudomonas* exotoxin disulfide linked conjugate. The invention also includes methods of making and using these toxins and pharmaceutical compositions.



WO 01/31020 A1



IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *With international search report.*
- *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

## **DISULFIDE CONJUGATED CELL TOXINS AND METHODS OF MAKING AND USING THEM**

### **CROSS REFERENCE TO RELATED APPLICATIONS**

- 5           The present application claims benefit of priority of U.S. Provisional Application No. 60/161,159 filed 10/22/99, which is herein incorporated by reference.

### **FIELD OF THE INVENTION**

- This invention generally pertains to the field of medicine and pain control.
- 10   In particular, this invention pertains to the discovery of novel disulfide linked cell toxins which can ablate neurokinin-1 (NK-1) receptor expressing cells. These toxins are particularly useful as pharmaceuticals for the treatment of chronic pain.

### **BACKGROUND OF THE INVENTION**

- NK-1 receptor expressing cells are expressed on a variety of cell types.
- 15   Thus, ablation of these cells can be a means to treat a variety of condition or modulate many different physiologic processes. For example, while pain-mediating cells and neurons are the predominant cells expressing NK-1 receptors (*e.g.*, spinal cord dorsal horn neurons, see *e.g.*, Basbaum (1999) Reg. Anesth. Pain Med. 24:59-67; brain cells, see, *e.g.*, Saria (1999) Eur. J. Pharmacol. 375:51-60; neostriatum cells through the axon
- 20   collaterals of spiny projection neurons, see, *e.g.*, Galaraga (1999) Synapse 33:26-35), a variety of other cells also express NK-1 receptors. Thus, although pain relief is a major result of the killing of NK-1 receptor expressing cells, many other conditions can also be treated. For example, spinal NK-1 receptors modulate autonomic reflexes, including the micturition reflex. In the peripheral nervous system, NK-1 receptors are widely
- 25   expressed in the respiratory, genitourinary and gastrointestinal tracts. NK-1 receptors are also expressed by several types of inflammatory and immune cells. In the cardiovascular system, NK-1 receptors mediate endothelium-dependent vasodilation and plasma protein extravasation. At respiratory level, NK-1 receptors mediate neurogenic inflammation which is especially evident upon exposure of the airways to irritants. In the carotid body,
- 30   NK-1 receptors mediate the ventilatory response to hypoxia. In the gastrointestinal

system, NK-1 receptors mediate smooth muscle contraction, regulate water and ion secretion and mediate neuro-neuronal communication. In the genitourinary tract, NK-1 receptors are widely distributed in the renal pelvis, ureter, urinary bladder and urethra and mediate smooth muscle contraction and inflammation in response to noxious stimuli.

5 NK-1 receptors antagonists, including toxins that can ablate NK-1 receptor expressing cells, may have several therapeutic applications at sites in both the central and peripheral nervous systems and tissues of the body. In the central nervous system, NK-1 receptor ablation toxins could be used to produce analgesia, as antiemetics and for treatment of certain forms of urinary incontinence due to detrusor hyperreflexia. In the peripheral  
10 nervous system, toxins of the invention could be used in several inflammatory diseases including arthritis, inflammatory bowel diseases and cystitis (Quartara (1998) *Neuropeptides* 32:1-49). Thus, there exists a need to develop a wide variety of NK-1 expressing cell toxins for use as treatments for a variety of different conditions and as modifiers of a variety of different physiologic mechanisms.

15               Toxins which kill NK-1 expressing cells can be used to treat pain. In particular demand are toxins which can treat chronic pain while at the same time not significantly affecting the ability to react to acutely painful, potentially dangerous, stimuli. Efforts to find more effective treatments of chronic pain which have few unwanted side effects or which do not dampen acutely painful potentially dangerous  
20 stimuli remains a continuing challenge. Current analgesic therapies often fall short of therapeutic goals and typically have unacceptable side effects. In many chronic pain syndromes, such as those subsequent to neuropathic injury, pain is not well controlled by any currently available method. Furthermore, most chronic pain treatment regimes affect the patient's ability to perceive acute pain, thus blunting or abrogating necessary  
25 protective basal nociceptive responses. Thus, the discovery of more efficacious and safe means to control chronic pain is unpredictable and therapeutically advantageous.

              An endogenous peptide ligand of NK-1 receptors is the eleven amino acid long peptide Substance P ("SP"). SP plays a central role in pain signaling by possibly transducing second messenger signals from primary afferent nociceptive terminals to  
30 second-order neurons in the spinal cord (see, *e.g.*, Lembeck (1981) *Neuropeptides* 1:175-180). SP transduces a pain signal by interacting primarily with NK-1 receptor-bearing cells in the brain and spinal chord (see, *e.g.*, Abbadie (1996) *Neuroscience* 70:201-209). Thus, one strategy to control pain has involved making SP antagonists or SP-based toxins that can selectively kill NK-1 receptor-bearing cells (see, *e.g.*, Iadarola (1997) *Science*

278:239-240; Fitzgerald, D., pp. 69 to 82, In Towards a New Pharmacotherapy of Pain, Ed. A.I. Basbaum et al., John Wiley & Sons Ltd. 1991). For example, Goettl, et al. inhibited a pain response in mice by intrathecal administration of an SP antagonist (Goettl (1998) Brain Res. 780:80-85). Fisher et al. demonstrated that a diphtheria toxin-SP recombinant protein selectively killed cultured cells stably transfected with and expressing NK-1 receptors (Fisher (1996) Neurobiol. 93:7344-7345). One group injected rats intrathecally with a saporin toxin-SP disulfide-linked conjugate. This conjugate killed NK-1 receptor bearing cells in the superficial lamina I of the spinal cord and reduced chronic but not acute pain sensation (Mantyh (1997) Science 278:275-279; Wiley (1997) Neurosci. Letters 230:97-100). Benoliel et al. selectively killed NK-1 receptor-bearing cells to reduce chronic pain in a rat animal model by intrathecal administration of an SP/diphtheria toxin recombinant protein. The recombinant protein killed NK-1 receptor-bearing cells and significantly reduced chronic pain as compared to acute pain (Benoliel (1999) Pain 79:243-253). Thus, because of the potential for treating the very refractive and unpredictable condition of chronic pain, new NK-1 receptor bearing cell toxins are needed.

In summary, there exists a need to develop a wide variety of NK-1 expressing cell toxins for use as treatments for a variety of different conditions and as modifiers of a variety of different physiologic mechanisms, particularly in the unpredictable field of chronic pain control. It is also extremely important to provide patients with end stage disease proper palliative care and new medications for control of severe intractable pain are needed for this population.

### SUMMARY OF THE INVENTION

The invention provides a method of making a cell toxin comprising reacting a polypeptide comprising a *Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain, wherein the *Pseudomonas* exotoxin translocation domain comprises at least one reactive sulfhydryl group, with a substance P peptide comprising one additional cysteine residue at its amino terminal end, wherein the cysteine sulfhydryl group is disulfide linked to a di-thiobis (2-nitro)-benzoic acid group, such that after the reaction a disulfide bond is formed between the exotoxin polypeptide and the substance P and a thionitrobenzoate group is released, and purifying the substance P-*Pseudomonas* exotoxin disulfide linked conjugate from the released thionitrobenzoate group such that the purified conjugate is substantially free of

thionitrobenzoate groups. In this method the *Pseudomonas* exotoxin translocation domain sulfhydryl group can be located within ten amino acid residues of the amino terminus or at the amino terminus. The *Pseudomonas* exotoxin translocation domain sulfhydryl group can be a cysteine residue or an equivalent, e.g., a peptidomimetic, an analog, a conservative substitution variation. The *Pseudomonas* exotoxin translocation domain can be covalently linked to the *Pseudomonas* exotoxin ADP-ribosylation domain, for example, the covalent linkage between the *Pseudomonas* exotoxin translocation domain and the *Pseudomonas* exotoxin ADP-ribosylation domain can be a peptide bond, or equivalent structure, as discussed below. The *Pseudomonas* exotoxin translocation domain can comprise an amino acid sequence as set forth in SEQ ID NO:1. The *Pseudomonas* exotoxin ADP-ribosylation domain can comprise an amino acid sequence as set forth in SEQ ID NO:2.

The invention also provides a pharmaceutical composition for the ablation of NK1 receptor expressing cells. The pharmaceutical composition comprises a cell toxin and a pharmaceutically acceptable excipient, wherein the cell toxin is a substance P-*Pseudomonas* exotoxin disulfide linked conjugate made by a process comprising the following steps: reacting a polypeptide comprising a *Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain, wherein the *Pseudomonas* exotoxin translocation domain comprises at least one reactive sulfhydryl group, with a substance P peptide comprising one additional cysteine residue at its amino terminal end, wherein the cysteine sulfhydryl group is disulfide linked to a di-thiobis (2-nitro)-benzoic acid group, such that after the reaction a disulfide bond is formed between the exotoxin polypeptide and the substance P and a thionitrobenzoate group is released, and purifying the substance P-*Pseudomonas* exotoxin disulfide linked conjugate from the released thionitrobenzoate group such that the purified conjugate is substantially free of thionitrobenzoate groups. The *Pseudomonas* exotoxin translocation domain sulfhydryl group can be located within ten amino acid residues of the amino terminus or it can be located at the amino terminus. The *Pseudomonas* exotoxin translocation domain sulfhydryl group can be a cysteine residue or equivalent residue, as discussed below. The *Pseudomonas* exotoxin translocation domain can covalently linked to the *Pseudomonas* exotoxin ADP-ribosylation domain, for example, the covalent linkage between the *Pseudomonas* exotoxin translocation domain and the *Pseudomonas* exotoxin ADP-ribosylation domain can be a peptide bond. The *Pseudomonas* exotoxin translocation domain can comprise an amino acid sequence as set forth in SEQ ID NO:1. The

*Pseudomonas* exotoxin ADP-ribosylation domain can comprise an amino acid sequence as set forth in SEQ ID NO:2. The cell toxin and pharmaceutically acceptable excipient can be suitable for administration intrathecally, subdurally, directly into the brain parenchyma, intraventricularly, or directly into a tumor (or systemic administration) for treatment of cancer cells that express a receptor that binds to SP (e.g., NK-1 receptor).

The invention also provides a method for ablating an NK1 receptor expressing cell in a patient comprising administering a cell toxin in a pharmaceutically acceptable excipient in an amount sufficient to ablate an NK1 receptor expressing cell, wherein the cell toxin is a substance P-*Pseudomonas* exotoxin disulfide linked conjugate made by a process comprising the following steps: reacting a polypeptide comprising a *Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain, wherein the *Pseudomonas* exotoxin translocation domain comprises at least one reactive sulfhydryl group, with a substance P peptide comprising one additional cysteine residue at its amino terminal end, wherein the cysteine sulfhydryl group is disulfide linked to a di-thiobis (2-nitro)-benzoic acid group, such that after the reaction a disulfide bond is formed between the exotoxin polypeptide and the substance P and a thionitrobenzoate group is released, and purifying the substance P-*Pseudomonas* exotoxin disulfide linked conjugate from the released thionitrobenzoate group such that the purified conjugate is substantially free of thionitrobenzoate groups. The ablated NK1 receptor expressing cell can be dorsal horn cells, neostriatal cells or other brain parenchyma cells. The ablated NK1 receptor expressing cell can also be inflammatory or immune cells, respiratory cells, genitourinary cells or gastrointestinal tract cells or tumor cells that express a receptor that binds SP (e.g., NK-1 receptor).

The invention also provides a method of treating chronic pain without significantly affecting basal nociceptive responses comprising administering a cell toxin in a pharmaceutically acceptable excipient in an amount sufficient to treat chronic pain without significantly affecting basal nociceptive responses, wherein the cell toxin is a substance P-*Pseudomonas* exotoxin disulfide linked conjugate made by a process comprising the following steps: reacting a polypeptide comprising a *Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain, wherein the *Pseudomonas* exotoxin translocation domain comprises at least one reactive sulfhydryl group, with a substance P peptide comprising one additional cysteine residue at its amino terminal end, wherein the cysteine sulfhydryl group is disulfide linked to a di-thiobis (2-nitro)-benzoic acid group, such that after the reaction a disulfide

bond is formed between the exotoxin polypeptide and the substance P and a thionitrobenzoate group is released, and purifying the substance P-*Pseudomonas* exotoxin disulfide linked conjugate from the released thionitrobenzoate group such that the purified conjugate is substantially free of thionitrobenzoate groups. The cell toxin can be administered, for example, in the form of a pharmaceutical composition, to epineurium cells, perineurium cells, nerve ganglia, nerve sheathes, nerve linings, meninges, pia mater cells, arachnoid membrane cells, dura membrane cells, cells lining a joint or brain or spinal cord parenchymal cells or tumor cells expressing the proper receptor. The pharmaceutical composition can be administered intrathecally or injected directly into spinal cord or brain parenchymal cells, or joint spaces, or intravenously. For example, the pharmaceutical composition can be delivered into the subarachnoid space through implanted or external intrathecal or epidural pumps.

A further understanding of the nature and advantages of the present invention is realized by reference to the remaining portions of the specification, the figures and claims.

All publications, patents and patent applications cited herein are hereby expressly incorporated by reference for all purposes.

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a schematic summary of data of experiments testing the ability of the SP-PE conjugate toxin of the invention to kill CHO cells stably transfected with and expressing NK-1 receptors (Fig. 1A), NK-2 receptors (Fig. 1B), and NK-3 receptors (Fig. 1C), as discussed in detail in Example 1, below.

Figure 2 shows a schematic summary of data of experiments testing the ability of the SP-PE conjugate toxin of the invention to treat pain (as determined by a thermal sensitivity test) in an art accepted (rat) animal model for pain control, as explained in detail in Example 3, below.

Figure 3 shows a schematic summary of data of experiments testing the segmental selectivity of SP-PE applied at sacral spinal cord.

Figure 4 shows a schematic summary of data of experiments testing the thermal sensitivity in rats at 46 days following intrathecal injection of SP-PE conjugate. The ability of the SP-PE conjugate toxin to treat pain effects in an inflammation model of chronic pain was also tested.



## DESCRIPTION OF THE INVENTION

This invention is the discovery of a of a novel disulfide linked cell toxin conjugate comprising a modified substance P ("SP") peptide and a modified

5 *Pseudomonas* exotoxin polypeptide. This novel cell toxin conjugate is particularly effective in ablating NK-1 receptor-expressing cells. Killing such cells is an effective means of treating a variety of conditions, particularly, chronic pain or tumors that express a receptor that binds SP, *e.g.*, NK-1 receptors.

The SP-PE toxins of the invention of particularly efficacious in treating  
10 patients with end stage cancer and other long term diseases associated with chronic pain who often need greater levels of pain control than currently available drugs can provide. Because the SP-PE toxins of the invention only kill NK-1 receptor expressing cells, they can be used effectively in combination with conventional pain-killing drugs, *e.g.*, opioids. The Examples below show that the SP-PE toxin of the invention only kills substance P  
15 receptor (NK-1 receptor)-expressing cells in the spinal cord but spares the opioid receptor expressing cells. Thus, the patient's capacity to be managed with opioids will not be impaired. Accordingly, the invention provides an advanced and improved pain management strategy that will provide greater pain relief. The needs of these chronic and severe pain patients are underserved and the toxins of the invention can be used to  
20 provide an additional level of palliative care by selectively deleting key components in the pain transmission circuit.

Furthermore, in animal model studies, appropriate doses of SP-PE can also block basal nociceptive responses without overtly impairing other functions such as locomotion. The fact that the toxin of the invention can be administered to alleviate pain  
25 without detectable motoric involvement expands the possible uses of SP-PE, particularly in patients that have problems such as cancer pain. For example, the SP-PE toxin can be used in patients have a chronic disease that causes intermittant problems with the pain system but chronic pain is always present. For example, bone metastasis to the sacral spinal column in prostate cancer makes it very painful to sit and move. This type of  
30 "acute" pain can be very effectively treated with the SP-PE toxins of the invention, whereas other drugs fail routinely.

The modified *Pseudomonas* exotoxin ("PE") polypeptide comprises a *Pseudomonas* exotoxin cell translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain. The *Pseudomonas* exotoxin translocation domain comprises

at least one reactive sulfhydryl group; one exemplary translocation domain has only one cysteine group (or equivalent, *e.g.*, a peptidomimetic); *e.g.*, at the residue corresponding to position 287 of the naturally expressed PE, as described below.

The SP peptide used in the toxin conjugate of the invention comprises one additional cysteine residue (or equivalent, *e.g.*, a peptidomimetic) at its amino terminal end. This amino terminal residue is disulfide linked to a di-thiobis (2-nitro)-benzoic acid group, or equivalent. After the reacting the modified PE (with only one active sulfhydryl group) and the modified SP together, a disulfide bond is formed between the exotoxin polypeptide and the SP. The reaction also results in release of a thionitrobenzoate (or equivalent, if used) group. This reaction results in a one to one molar basis between the disulfide linked SP and PE groups. The SP peptide is also amidated at its carboxy terminal amino acid residue (or equivalent), as discussed below.

The toxin conjugate is then purified from the released thionitrobenzoate group such that the purified conjugate is substantially free of thionitrobenzoate groups, *i.e.*, the purified toxin conjugate preparation less than about 2% (on a molar basis) thionitrobenzoate groups remaining. Thus, the pharmaceutical compositions of the invention have less than 2% thionitrobenzoate. The invention also comprises toxin conjugate preparations that have less than 1%, and 0.5%, and 0.25% "contaminating" thionitrobenzoate (or equivalent, if used) group.

In alternatively embodiments, in place of SP, neuropeptide FF, Neuropeptide Y, preproenkephalin derived peptides, preprodynorphin peptides, other tachykinin peptides, neurotensin, calcitonin gene related peptide and its fragments can be conjugated to PE.

In studies described in the Examples, below, CHO cells stably transfected with and expressing NK-1 receptors, but not NK-2 or NK-3 receptors, were killed by the cell toxin conjugate of the invention. Toxicity to NK-1 receptor expressing cells was blocked by the addition of excess free SP or by treating the toxin conjugate with an anti-SP antibody. Cytotoxicity occurred with exposure times to toxin as short as a two minutes (lethality assessed at 24 hours after exposure). The toxin conjugate of the invention was extremely effective in deleting NK-1 receptor expressing cells from the dorsal horn of the spinal cord and NK-1 receptor expressing cells from the striatum. The data described in the Examples, below, demonstrate that the toxin conjugate of the invention can kill NK-1 receptor expressing cells, *e.g.*, ablate neurons when administered

into the cerebral spinal fluid space (CSF) and when administered directly into the brain parenchyma.

## DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this invention belongs. As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

The term "administering" incorporates the common usage and refers to any appropriate means to give a pharmaceutical to a patient, taking into consideration the pharmaceutical composition and the preferred site of administration (*e.g.*, in a preferred embodiment, the pharmaceutical composition of the invention is injected into the subarachnoid space as an aqueous solution).

The term "basal nociceptive responses" incorporates its common usage and refers to baseline responses to nociceptive, or painful, stimuli.

The terms "chronic pain" and "acute pain" incorporate their common usages; subjective (*e.g.*, clinical diagnosis) and objective means (*e.g.*, laboratory tests, PET) to determine the presence of chronic pain and/or acute pain, and to distinguish between these two distinct categories of pain, are described in detail, herein.

The term "pharmaceutically acceptable excipient" incorporates the common usage and includes any suitable pharmaceutical excipient, including, *e.g.*, water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose, lactose, or sucrose solutions, magnesium stearate, sodium stearate, glycerol monostearate, glycerol, propylene glycol, ethanol, and the like.

The terms "polypeptide" and "peptide" including "*Pseudomonas* exotoxin translocation domain, "*Pseudomonas* exotoxin ADP-ribosylation domain" and "substance P" (or "SP") peptide includes polypeptides and peptides having an activity and a structural characteristic which substantially corresponds to their corresponding polypeptides. These include "analogs," "conservative variants," "peptidomimetics" and "mimetics" with structures and activity which substantially correspond to exemplary sequences. For example, an exemplary, modified *Pseudomonas* exotoxin translocation domain comprises an amino acid sequence as set forth in SEQ ID NO:1 (with only one cysteine residue, as discussed below) and an exemplary *Pseudomonas* exotoxin ADP-ribosylation domain comprises an amino acid sequence as set forth in SEQ ID NO:2

(residues 400 to 613 of SEQ ID NO:6). The amino acid sequences set forth in the present application use the conventional practice wherein the amino group is presented to the left (the N-terminus) and the carboxyl group to the right (the C-terminus) of each amino acid residue.

5 Human substance P ("SP") is an eleven amino acid peptide having the sequence RPKPQQFFGLM (SEQ ID NO:3). Naturally occurring SP is amidated on its carboxy terminus. The invention uses a modified twelve residue SP peptide – a cysteine residue (or equivalent) is added to the amino terminus; CRPKPQQFFGLM (SEQ ID NO:4), and, the carboxy terminal amino acid residue (or equivalent) is amidated (in one  
10 embodiment, the SP is made synthetically, amidated, conjugated to TNB and then disulfide linked to PE). The "polypeptides" and "peptides" of the invention include "conservative variants" and "analogs" which have modified amino acid sequences such that the change(s) do not substantially alter the polypeptide's (the conservative variant's) structure and/or activity. Structural variations to the SP or PE moieties may  
15 advantageously alter potency, selectivity or stability to enzymatic degradation.

Thus, a substance P peptides or variants or mimetic thereof are within the scope of the invention if they are capable of binding to an NK-1 receptor expressed on a eukaryotic cell, such as a human cell (binding protocols for such determinations are well known in the art, see, *e.g.*, Ciucci (1998) Br. J. Pharmacol. 125:393-401; Maguire (1998)  
20 Brain Res. 786:263-266). Alternatively, a non-natural residue (*e.g.*, peptidomimetic) comprising a sulfhydryl or equivalent moiety can be designed to replace the cysteine on the N-terminus of the modified SP peptide used in the toxin conjugates of the invention.

*Pseudomonas* exotoxin translocation domain variants or mimetics thereof are within the scope of the invention if they are capable of translocating through an  
25 endosomal/ microsomal membrane into the cytosol (means for such determinations are well known in the art, see, *e.g.*, Theuer (1994) Biochemistry 33:5894-5900). A *Pseudomonas* exotoxin ADP-ribosylation domain variant or mimetic thereof is within the scope of the invention if, after translocation to the cytosol, can inhibit protein synthesis by ADP-ribosylating elongation factor 2 (means for such determinations are well known in  
30 the art, see, *e.g.* Zdanovsky (1993) J. Biol. Chem. 268(29):21791-21799; or, the method of Collier and Kandel, as described in Mansfield (1998) Bioconjugate Chem. 7:557-583, p. 558). The cell killing effectiveness of the cell toxin can be determined using any cytotoxicity assay, many of which are well known in the art (*e.g.*, cell death quantitated using the MTT method of Mosmann (1983) J. Immunol. Meth. 65: 55-63).

These include conservatively modified variations of an amino acid sequence, i.e., amino acid substitutions, additions or deletions of those residues that are not critical for protein or peptide activity, or substitution of amino acids with residues having similar properties (e.g., acidic, basic, positively or negatively charged, polar or non-polar, etc.) such that the substitutions of even critical amino acids does not substantially alter structure and/or activity. Conservative substitution tables providing functionally similar amino acids are well known in the art. For example, one exemplary guideline to select conservative substitutions includes (original residue followed by exemplary substitution): ala/gly or ser; arg/ lys; asn/ gln or his; asp/glu; cys/ser; gln/asn; gly/asp; gly/ala or pro; his/asn or gln; ile/leu or val; leu/ile or val; lys/arg or gln or glu; met/leu or tyr or ile; phe/met or leu or tyr; ser/thr; thr/ser; trp/tyr; tyr/trp or phe; val/ile or leu. An alternative exemplary guideline uses the following six groups, each containing amino acids that are conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); (see also, e.g., Creighton (1984) *Proteins*, W.H. Freeman and Company; Schulz and Schimer (1979) *Principles of Protein Structure*, Springer-Verlag). One of skill in the art will appreciate that the above-identified substitutions are not the only possible conservative substitutions. For example, for some purposes, one may regard all charged amino acids as conservative substitutions for each other whether they are positive or negative. In addition, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence can also be considered "conservatively modified variations." Routine experimentation will determine whether a conservative variant, analog, mimetic or the like is within the scope of the invention, i.e., that its structure and/or function is not substantially altered; exemplary means are well known, as described herein.

The terms "mimetic" and "peptidomimetic" refer to a synthetic chemical compound which has substantially the same structural and/or functional characteristics of the *Pseudomonas* exotoxin translocation domain, *Pseudomonas* exotoxin ADP-ribosylation domain and "SP" polypeptides and peptides of the invention. The mimetic can be either entirely composed of synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids. The mimetic can also incorporate any amount of natural amino acid

conservative substitutions as long as such substitutions also do not substantially alter the mimetic's structure and/or activity. As with polypeptides of the invention which are conservative variants, routine experimentation (as discussed herein) will determine whether a mimetic is within the scope of the invention, i.e., that its structure and/or function is not substantially altered. Polypeptide mimetic compositions can contain any combination of nonnatural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like.

The term "linked" means polypeptide domains or individual residues are joined, or "linked" by means other than natural peptide bonds. These include, e.g., electrostatic (e.g., ionic, van der Waals or hydrogen bonds) or chemical means. For example, the cell toxins of the invention comprise a *Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain. Polypeptide domains or individual peptidomimetic residues can be joined by peptide bonds or other chemical bonds or coupling means, such as, e.g., glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIC). Linking groups that can be an alternative to the traditional amide bond ("peptide bond") linkages include, e.g., ketomethylene (e.g., -C(=O)-CH<sub>2</sub>- for -C(=O)-NH-), aminomethylene (CH<sub>2</sub>-NH), ethylene, olefin (CH=CH), ether (CH<sub>2</sub>-O), thioether (CH<sub>2</sub>-S), tetrazole (CN<sub>4</sub>-), thiazole, retroamide, thioamide, or ester (see, e.g., Spatola (1983) in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. 7, pp 267-357, "Peptide Backbone Modifications," Marcell Dekker, NY).

A polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues. Nonnatural residues are well described in the scientific and patent literature; a few exemplary nonnatural compositions useful as mimetics of natural amino acid residues and guidelines are described below. Mimetics of aromatic amino acids can be generated by replacing by, e.g., D- or L- naphylalanine; D- or L- phenylglycine; D- or L-2 thieneylalanine; D- or L-1, -2, 3-, or 4- pyreneylalanine; D- or L-3 thieneylalanine; D- or L-(2-pyridinyl)-alanine; D- or L-(3-pyridinyl)-alanine; D- or L-(2-pyrazinyl)-alanine; D-

or L-(4-isopropyl)-phenylglycine; D-(trifluoromethyl)-phenylglycine; D-(trifluoromethyl)-phenylalanine; D-p-fluorophenylalanine; D- or L-p-biphenylphenylalanine; K- or L-p-methoxybiphenylphenylalanine; D- or L-2-indole(alkyl)alanines; and, D- or L-alkylainines, where alkyl can be substituted or unsubstituted methyl, ethyl, propyl, hexyl, butyl, pentyl, isopropyl, iso-butyl, sec-isotyl, iso-pentyl, or a non-acidic amino acids.

Aromatic rings of a nonnatural amino acid include, *e.g.*, thiazolyl, thiophenyl, pyrazolyl, benzimidazolyl, naphthyl, furanyl, pyrrolyl, and pyridyl aromatic rings. Mimetics of acidic amino acids can be generated by substitution by, *e.g.*, non-carboxylate amino acids while maintaining a negative charge; (phosphono)alanine; sulfated threonine. Carboxyl side groups (*e.g.*, aspartyl or glutamyl) can also be selectively modified by reaction with carbodiimides ( $R'-N-C-N-R'$ ) such as, *e.g.*, 1-cyclohexyl-3(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3(4-azonia- 4,4- dimetholpentyl) carbodiimide. Aspartyl or glutamyl can also be converted to asparaginy and glutaminy residues by reaction with ammonium ions. Mimetics of basic amino acids can be generated by substitution with, *e.g.*, (in addition to lysine and arginine) the amino acids ornithine, citrulline, or (guanidino)-acetic acid, or (guanidino)alkyl-acetic acid, where alkyl is defined above.

Nitrile derivative (*e.g.*, containing the CN-moiety in place of COOH) can be substituted for asparagine or glutamine. Asparaginy and glutaminy residues can be deaminated to the corresponding aspartyl or glutamyl residues. Arginine residue mimetics can be generated by reacting arginy with, *e.g.*, one or more conventional reagents, including, *e.g.*, phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, or ninhydrin, preferably under alkaline conditions. Tyrosine residue mimetics can be generated by reacting tyrosyl with, *e.g.*, aromatic diazonium compounds or tetranitromethane. N-acetylimidizol and tetranitromethane can be used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Cysteine residue mimetics can be generated by reacting cysteiny residues with, *e.g.*, alpha-haloacetates such as 2-chloroacetic acid or chloroacetamide and corresponding amines; to give carboxymethyl or carboxyamidomethyl derivatives. Cysteine residue mimetics can also be generated by reacting cysteiny residues with, *e.g.*, bromo-trifluoroacetone, alpha-bromo-beta-(5-imidozoyl) propionic acid; chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide; methyl 2-pyridyl disulfide; p-chloromercuribenzoate; 2-chloromercuri-4-nitrophenol; or, chloro-7-nitrobenzo-oxa-1,3-diazole. Lysine mimetics can be generated (and amino terminal residues can be altered) by reacting lysiny with, *e.g.*, succinic or other carboxylic acid anhydrides. Lysine and other alpha-amino-containing residue

mimetics can also be generated by reaction with imidoesters, such as methyl picolinimide, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4, pentanedione, and transamidase-catalyzed reactions with glyoxylate. Mimetics of methionine can be generated by reaction with, *e.g.*, methionine sulfoxide. Mimetics of proline include, *e.g.*, pipecolic acid, thiazolidine carboxylic acid, 3- or 4- hydroxy proline, dehydropyrolidine, 3- or 4-methylproline, or 3,3,-dimethylproline. Histidine residue mimetics can be generated by reacting histidyl with, *e.g.*, diethylprocarbonate or para-bromophenacyl bromide. Other mimetics include, *e.g.*, those generated by hydroxylation of proline and lysine; phosphorylation of the hydroxyl groups of seryl or threonyl residues; methylation of the alpha-amino groups of lysine, arginine and histidine; acetylation of the N-terminal amine; methylation of main chain amide residues or substitution with N-methyl amino acids; or amidation of C-terminal carboxyl groups.

A naturally occurring amino acid in a polypeptide or peptide of the invention can be replaced by a natural or synthetic amino acid or peptidomimetic residue of the opposite chirality. Thus, any amino acid naturally occurring in the L-configuration (which can also be referred to as the R or S, depending upon the structure of the chemical entity) can be replaced with the amino acid of the same chemical structural type or a peptidomimetic, but of the opposite chirality, generally referred to as the D- amino acid, but which can additionally be referred to as the R- or S- form.

The mimetics of the invention can also include compositions that contain a structural mimetic residue, particularly a residue that induces or mimics secondary structures, such as a beta turn, beta sheet, alpha helix structures, gamma turns, and the like. For example, substitution of natural amino acid residues with D-amino acids; N-alpha-methyl amino acids; C-alpha-methyl amino acids; or dehydroamino acids within a peptide can induce or stabilize beta turns, gamma turns, beta sheets or alpha helix conformations. Beta turn mimetic structures have been described, *e.g.*, by Nagai (1985) Tet. Lett. 26:647-650; Feigl (1986) J. Amer. Chem. Soc. 108:181-182; Kahn (1988) J. Amer. Chem. Soc. 110:1638-1639; Kemp (1988) Tet. Lett. 29:5057-5060; Kahn (1988) J. Molec. Recognition 1:75-79. Beta sheet mimetic structures have been described, *e.g.*, by Smith (1992) J. Amer. Chem. Soc. 114:10672-10674. For example, a type VI beta turn induced by a cis amide surrogate, 1,5-disubstituted tetrazol, is described by Beusen (1995) Biopolymers 36:181-200. Incorporation of achiral omega-amino acid residues to generate polymethylene units as a substitution for amide bonds is described by Banerjee



(1996) Biopolymers 39:769-777. Secondary structures of polypeptides can be analyzed by, *e.g.*, high-field <sup>1</sup>H NMR or 2D NMR spectroscopy, see, *e.g.*, Higgins (1997) J. Pept. Res. 50:421-435. See also, Hruby (1997) Biopolymers 43:219-266, Balaji, et al., U.S. Pat. No. 5,612,895.

- 5           The skilled artisan will recognize that individual synthetic residues and polypeptides incorporating mimetics can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature, *e.g.*, Organic Syntheses Collective Volumes, Gilman et al. (Eds) John Wiley & Sons, Inc., NY. Polypeptides incorporating mimetics can also be made using solid phase synthetic
- 10   procedures, as described, *e.g.*, by Di Marchi, et al., U.S. Pat. No. 5,422,426. Mimetics of the invention can also be synthesized using combinatorial methodologies. Various techniques for generation of peptide and peptidomimetic libraries are well known, and include, *e.g.*, multipin, tea bag, and split-couple-mix techniques; see, *e.g.*, al-Obeidi (1998) Mol. Biotechnol. 9:205-223; Hruby (1997) Curr. Opin. Chem. Biol. 1:114-119;
- 15   Ostergaard (1997) Mol. Divers. 3:17-27; Ostresh (1996) Methods Enzymol. 267:220-234.

          The term "pia mater connective tissue" incorporates the common usage refers to the tissue, membrane, or connective tissue which separates the parenchyma of the spinal cord from the subarachnoid space (the cerebral spinal fluid (CSF) space).

- The term "spinal cord parenchymal tissue" incorporates the common usage
- 20   and refers to the body of the spinal cord containing nerve tissue, *e.g.*, white and gray mater.

          The term "subarachnoid space" or cerebral spinal fluid (CSF) space incorporates the common usage refers to the anatomic space between the pia mater and the arachnoid membrane containing CSF.

- 25           The term "substantially free of thionitrobenzoate groups" means that the toxin conjugate is then purified from the released thionitrobenzoate (or its equivalent, if used) group such that the purified conjugate is substantially free of thionitrobenzoate groups, *i.e.*, the purified toxin conjugate preparation less than about 2% (on a molar basis) thio-nitrobenzoate (or equivalent) groups remaining. Thus, the pharmaceutical
- 30   compositions of the invention have less than 2% thionitrobenzoate. In alternative embodiments, toxin conjugate preparations (including pharmaceuticals of the invention) that have less than 1%, and 0.5%, and 0.25% "contaminating" thionitrobenzoate (or equivalent) group.

The term "treating" refers to any indicia of success in the treatment or amelioration of an injury, pathology, condition, or symptom (*e.g.*, pain), including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the symptom, injury, pathology or condition more tolerable to the patient; 5 decreasing the frequency or duration of the symptom or condition; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being; or, in some situations, preventing the onset of the symptom or condition, *e.g.*, pain. The treatment or amelioration of symptoms can be based on any objective or subjective parameter; including, *e.g.*, the results of a 10 physical examination and/or a psychiatric evaluation, or, simply an improvement in the patient's sense of well-being. For example, the methods of the invention selectively treats chronic pain by ameliorating the hyperalgesia associated with chronic pain, while not significantly affecting basal nociceptive responses.

#### **Distinguishing Chronic from Acute Pain**

15 Pain is always subjective and can have physiologic, pathophysiologic, psychologic, emotional, and affective dimensions. Pain causation can be broadly categorized as organic or psychogenic. Basically, two types of pain exist - acute pain and chronic pain. Each possibly is mediated by anatomically different nerves. Each type of pain has a different physiologic role. For example, the ability to perceive and respond 20 to "acutely" painful stimuli, which usually has the potential to cause tissue damage, serves a protective role for the individual. While many treatments for acute pain cannot ameliorate chronic pain (this, in fact, is used as one means to objectively identify "chronic" versus "acute" pain, as discussed below), before this invention, there existed no effective therapies to treat chronic pain without the unwanted side effect of significantly 25 dampening protective acute pain responses.

#### **Diagnosing and Assessing Chronic Pain**

The invention provides methods of treating chronic pain while at the same time not significantly affecting the ability to respond to acutely painful, and potentially harmful, stimuli. Thus, proper diagnosis of chronic pain aids in the practice and 30 assessment of efficacy (*e.g.*, for a particular dosage regimen or mode of administration) of the compositions and methods of the invention. Means to diagnosis chronic pain include classical clinical and psychological evaluations, which can be augmented by various

laboratory procedures, as described herein. Such means are well-described in the medical/scientific and patent literature; some illustrative examples are provided below.

One criteria to diagnose a "chronic" pain is whether the pain persists for a month beyond the usual course of an acute disease or a reasonable time for an injury to heal. This evaluation is made by the clinician on a case by case basis. Acute diseases or injuries can heal in 2, 3, or, at most, 6 weeks, depending on the nature of the condition or injury, the age and health of the patient, and the like. Clinicians are trained to be very aware of this "acute" versus "chronic" pain distinction, for it is critical to make correct diagnosis and treatment plans. For example, a simple wrist fracture can remain painful for a week to ten days; however, if pain persists longer than this period, a dystrophy could be developing which will be irreversible if not treated. See, *e.g.*, Bonica, et al., (1990) "Management of Pain," 2nd Ed., Vol. I, Lea & Feibiger, Phil., PA; Wall and Melzack (1994) "Textbook of Pain," Churchill Livingstone, NY. Accordingly, a chronic pain is diagnosed by the practitioner based on clinical and laboratory results, depending on the particular condition or injury, patient, and the like (see also, *e.g.*, Russo (1998) *Annu. Rev. Med.* 49:123-133).

Another means to identify a "chronic" pain is by diagnosis of a pathologic process (which is usually also chronic) known to produce or be associated with chronic pain. Such conditions are well characterized and include, *e.g.*, chronic pain syndrome (see, *e.g.*, Clifford (1993) *Can. Fam. Physician* 39:549-559), arthralgia, arthritis (*e.g.*, osteoarthritis and rheumatoid arthritis), causalgia, hyperpathia, neuralgia, neuritis, radiculagia, fibromyalgia (see, *e.g.*, Simms (1998) *Am. J. Med. Sci.* 315:346-350), orofacial pain and temporomandibular disorders (see, *e.g.*, Binderman (1997) *Curr. Opin. Periodontol.* 4:144-15), reflex sympathetic dystrophy (see, *e.g.*, Dangel (1998) *Paediatr. Anaesth.* 8:105-112, chronic back pain, certain cancers, and the like.

Chronic pain is also associated with particular injuries to the nerves. These include, *e.g.*, nerve transection (traumatic or surgical), chronic abnormal pressure on a nerve, chemical (*e.g.*, formalin) destruction of nerve tissue, and the like.

Chronic pain can also be distinguished from acute pain by its non-responsiveness to pharmacologic therapies known to significantly ameliorate or abate acute pain. When pain is initially diagnosed as acute or of unknown etiology, the clinician typically administers one of several analgesics known in the art to be effective for acute pain, such as, *e.g.*, a non-steroid anti-inflammatory drug (NSAID), such as, *e.g.*, aspirin, ibuprofen, propoxyphene, tramadol, acetaminophen and the like (see, *e.g.*, Tramer

(1998) Acta Anaesthesiol. Scand. 42:71-79). If there is no significant amelioration of pain, as assessed by the clinician, over an approximately six week period, then a provisional diagnosis of chronic pain can be made. Ultimately, as discussed above, a diagnosis of chronic pain depends upon determination as to whether pain would be expected, given each individual situation.

Other treatments to which chronic pain is also typically incompletely or totally unresponsive include tricyclic antidepressant administration, psychotherapy, or alternative medicines, such as acupuncture, biofeedback, and the like.

Laboratory, radiographic and other types of imaging procedures can also be used to diagnose chronic pain. In particular, positron emission tomography, or PET, now allows the clinician to objectify such otherwise merely subjective symptoms, including chronic pain (see, e.g., Reiss (1998) Fortschr. Med. 116:40-43; Di Piero (1991) Pain 46:9-12).

#### **SP Peptides and PE Polypeptide Domains**

The invention provides pharmaceutical compositions comprising polypeptide cell toxins in a pharmaceutically acceptable excipient. The invention also provides methods of making and using these pharmaceutical compositions to treat a variety of conditions responsive to the ablation of NK-1 receptor expressing cell, e.g., chronic pain. The invention can be practiced in conjunction with any method or protocol known in the art, which are well described in the scientific and patent literature. Therefore, only a few general techniques will be described prior to discussing specific methodologies and examples relative to the novel reagents and methods of the invention.

##### *General Techniques*

The polypeptide domains and peptides which comprise the cell toxin conjugates of the invention can be genetically engineered and/or expressed recombinantly. Techniques for the manipulation of nucleic acids, such as, e.g., subcloning into expression vectors, labeling probes, sequencing DNA, DNA hybridization are described in the scientific and patent literature, see e.g., Sambrook, ed., MOLECULAR CLONING: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989) ("Sambrook"); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel, ed. John Wiley & Sons, Inc., New York (1997) ("Ausubel"); and, LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY: HYBRIDIZATION WITH NUCLEIC ACID PROBES, Part I. Theory and Nucleic Acid

Preparation, Tijssen, ed. Elsevier, N.Y. (1993) ("Tijssen"). Product information from manufacturers of biological reagents and experimental equipment also provide information regarding known biological methods. Nucleic acids can also be generated or quantitated using amplification techniques. Suitable amplification methods include, but are not limited to: polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, ed. Innis, Academic Press, N.Y. (1990), ligase chain reaction (LCR) (Barringer (1990) Gene 89:117); and the like.

Alternatively, peptides and polypeptide domains used to practice the invention can be chemically synthesized *in vitro*, whole or in part, using chemical methods well known in the art; see *e.g.*, Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Horn (1980) Nucleic Acids Res. Symp. Ser. 225-232; Banga, A.K., Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, PA ("Banga"). For example, peptide synthesis can be performed using various solid-phase techniques (see *e.g.*, Roberge (1995) Science 269:202; Merrifield (1997) Methods Enzymol. 289:3-13) and automated synthesis may be achieved, *e.g.*, using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

The skilled artisan will recognize that individual synthetic residues and polypeptides incorporating mimetics can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature, *e.g.*, Organic Syntheses Collective Volumes, Gilman, et al. (Eds) John Wiley & Sons, Inc., NY. Polypeptides incorporating mimetics can also be made using solid phase synthetic procedures, as described, *e.g.*, by Di Marchi, et al., U.S. Pat. No. 5,422,426. Peptides and peptide mimetics of the invention can also be synthesized using combinatorial methodologies. Various techniques for generation of peptide and peptidomimetic libraries are well known, and include, *e.g.*, multipin, tea bag, and split-couple-mix techniques; see, *e.g.*, al-Obeidi (1998) Mol. Biotechnol. 9:205-223; Hruby (1997) Curr. Opin. Chem. Biol. 1:114-119; Ostergaard (1997) Mol. Divers. 3:17-27; Ostresh (1996) Methods Enzymol. 267:220-234. Modified peptides of the invention can be further produced by chemical modification methods, see, *e.g.*, Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896.

Nucleic acids, peptides and proteins, analogs and mimetics thereof, can be detected and quantified by any of a number of general means well known to those of skill

in the art. These include, *e.g.*, analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffusion chromatography, various immunological methods, such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, Southern analysis, Northern analysis, Dot-blot analysis, gel electrophoresis (*e.g.*, SDS-PAGE), RT-PCR, quantitative PCR, other nucleic acid or target or signal amplification methods, radiolabeling, scintillation counting, and affinity chromatography.

*Pseudomonas* exotoxin A

Following SP-NK-1 receptor binding on the cell surface, the ligand-receptor complex is internalized. This makes the NK-1 receptor a rational target for toxin-derived therapeutics. *Pseudomonas* exotoxin is a member of a protein family functionally characterized and a "reverse internalized predator." Toxins in this class act in the cytosol of mammalian cells to inhibit protein synthesis and cause cell death at very low concentrations. These toxins use the endocytosis pathway to gain entry to intracellular sorting vesicles, where they unfold and translocated into the cytosol. After translocation they refold and enzymatically inhibit protein synthesis. Because of high enzymatic catalytic rates and apparent resistance of these toxins to proteosome degradation, only one or a few molecules need to reach to cytosol to be effective.

Naturally expressed *Pseudomonas* exotoxin A can be used as a model to design toxin polypeptide domains to be used in the toxin conjugates of the invention. The naturally expressed toxin is secreted by *Pseudomonas aeruginosa* as a 67 kD protein composed of three prominent globular domains, termed Ia, II, and III. A small subdomain, termed Ib, connects domains II and III (see, *e.g.*, Allured (1986) Proc. Natl. Acad. Sci. 83:1320-1324).

Domain Ia of PE mediates cell binding. In nature, domain Ia binds to the low density lipoprotein receptor-related protein ("LRP"), also known as the  $\alpha$ 2-macroglobulin receptor (" $\alpha$ 2-MR") (see, *e.g.*, Kounnas (1992) J. Biol. Chem. 267:12420-23). Domain Ia of PE spans amino acids residues 1 to 252. While cell toxin conjugates of the invention lack a functional PE cell binding domain (replaced by SP in the conjugate), some residues of this domain may remain in the polypeptide comprising the

*Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain.

The *Pseudomonas* exotoxin translocation domain, or domain II, mediates translocation of the polypeptide from the endosome/ microsome to the cytosol. Domain II spans amino acids 253 to 364 in naturally occurring PE (see SEQ ID NO:6, below). An amino acid domain sufficient to effect translocation can be derived from the translocation domain of native PE. The translocation domain can include the entire sequence of domain II. However, the entire sequence is not necessary for translocation. For example, the amino acid sequence can minimally contain, *e.g.*, amino acids 280-344 (see SEQ ID NO:6, below) of domain II of PE. Sequences outside this region, *i.e.*, amino acids 253-279 and/or 345-364, can be eliminated from the domain. This domain also can be engineered with substitutions, analogs, mimetic, and the like, so long as translocation activity is retained. The translocation domain can function as follows. After binding to a receptor on the cell surface, the toxin enters the cell by endocytosis through clathrin-coated pits. In the naturally expressed PE, residues 265 and 287 are cysteines that form a disulfide loop. Once internalized into endosomes having an acidic environment, the peptide is cleaved by the protease furin between Arg279 and Gly280. Then, the disulfide bond is reduced (a mutation at Arg279 inhibits proteolytic cleavage and subsequent translocation to the cytosol, Ogata (1990) J. Biol. Chem. 265:20678-20685). However, a fragment of PE containing the sequence downstream of Arg279 (called "PE37") retains substantial ability to translocate to the cytosol (Siegall (1989) J. Biol. Chem. 264:14256-14261). Sequences in domain II beyond amino acid 345 also can be deleted without inhibiting translocation. Furthermore, amino acids at positions 339 and 343 appear to be necessary for translocation (Siegall (1991) Biochemistry 30:7154-7159). Methods for determining the functionality of a translocation domain are well known in the art, as noted above and described herein.

Domain Ib of PE has no known function. It spans amino acids 365 to 399 of the naturally occurring toxin.

The *Pseudomonas* exotoxin ADP-ribosylation domain, or domain III, is responsible for cytotoxicity. The naturally expressed PE includes an endoplasmic reticulum retention sequence which may be retained in the toxin polypeptide of the invention. Domain III mediates ADP ribosylation of elongation factor 2 ("EF-2") to inactivate protein synthesis. Domain III of PE spans amino acids 400 to 613. PE is "non-toxic" if it lacks EF-2 ADP ribosylation activity. Genetically modified forms of PE are

described in, *e.g.*, Pastan et al., United States patent 5,602,095; Pastan et al., United States patent 5,512,658 and Pastan et al., United States patent 5,458,878. As noted above, *Pseudomonas* exotoxin translocation domain and *Pseudomonas* exotoxin ADP-ribosylation domain (and "substance P peptide) include polypeptides having an activity and a structural characteristic which substantially corresponds to their corresponding polypeptides, including "analogs," "conservative variants," "peptidomimetics" and "mimetics."

An exemplary *Pseudomonas* exotoxin translocation domain comprises an amino acid sequence as set forth in SEQ ID NO:1, which has an amino acid sequence the same as residues 280 to 364 of SEQ ID NO:6 (domain Ib has been deleted, see below) *except* that an initiating methionine is used as residue in place of the glycine at residue 280 (in naturally occurring SEQ ID NO:6) (see also Theur (1993) Cancer Res. 53:340-347).

SEQ ID NO:1:

Met Trp Glu Gln Leu Glu Gln Cys Gly Tyr Pro Val Gln Arg Leu Val Ala Leu  
Tyr Leu Ala Ala Arg Leu Ser Trp Asn Gln Val Asp Gln Val Ile Arg Asn Ala  
Leu Ala Ser Pro Gly Ser Gly Gly Asp Leu Gly Glu Ala Ile Arg Glu Gln Pro  
Glu Gln Ala Arg Leu Ala Leu Thr Leu Ala Ala Ala Glu Ser Glu Arg Phe Val  
Arg Gln Gly Thr Gly Asn Asp Glu Ala Gly Ala Ala Asn

An exemplary *Pseudomonas* exotoxin ADP-ribosylation domain comprises an amino acid sequence as set forth in SEQ ID NO:2, which corresponds to amino acids 400 to 613 of SEQ ID NO:6.

SEQ ID NO:2:

Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr Gln Asn  
Trp Thr Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu Glu Arg  
Gly Tyr Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln  
Ser Ile Val Phe Gly Gly Val Arg Ala Arg Ser Gln Asp Leu Asp Ala  
Ile Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly  
Tyr Ala Gln Asp Gln Glu Pro Asp Ala Arg Gly Arg Ile Arg Asn Gly  
Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Pro Gly Phe Tyr  
Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu Val Glu



Arg Leu Ile Gly His Pro Leu Pro Leu Arg Leu Asp Ala Ile Thr Gly  
 Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro Leu  
 5 Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp Pro Arg  
 Asn Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys Glu Gln  
 10 Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys Pro Pro  
 Arg Glu Asp Leu Lys

The polypeptides of the invention include conservative variants, mimetics  
 15 and analogs which have modified amino acid sequences such that the change(s) do not  
 substantially alter the variants activity. Thus, a *Pseudomonas* exotoxin translocation  
 domain with conservative variants is within the scope of the invention if it is capable of  
 translocating through an endosomal/ microsomal membrane into the cytosol (means for  
 such determinations are well known in the art, see, *e.g.*, Theuer (1994) *supra*).

20 A *Pseudomonas* exotoxin ADP-ribosylation domain with conservative  
 variants is within the scope of the invention if, after translocation to the cytosol, can  
 inhibit protein synthesis by ADP-ribosylating elongation factor 2 (means for such  
 determinations are well known in the art, see, *e.g.* Zdanovsky (1993) *supra*).

The nucleotide sequence (SEQ ID NO:5) and deduced amino acid  
 25 sequence (SEQ ID NO:6) of *Pseudomonas aeruginosa* exotoxin A are:

	GCC GAA GAA GCT TTC GAC CTC TGG AAC GAA TGC GCC AAA GCC TGC GTG	48
	Ala Glu Glu Ala Phe Asp Leu Trp Asn Glu Cys Ala Lys Ala Cys Val	
	1 5 10 15	
30	CTC GAC CTC AAG GAC GGC GTG CGT TCC AGC CGC ATG AGC GTC GAC CCG	96
	Leu Asp Leu Lys Asp Gly Val Arg Ser Ser Arg Met Ser Val Asp Pro	
	20 25 30	
35	GCC ATC GCC GAC ACC AAC GGC CAG GGC GTG CTG CAC TAC TCC ATG GTC	144
	Ala Ile Ala Asp Thr Asn Gly Gln Gly Val Leu His Tyr Ser Met Val	
	35 40 45	
40	CTG GAG GGC GGC AAC GAC GCG CTC AAG CTG GCC ATC GAC AAC GCC CTC	192
	Leu Glu Gly Gly Asn Asp Ala Leu Lys Leu Ala Ile Asp Asn Ala Leu	
	50 55 60	
	AGC ATC ACC AGC GAC GGC CTG ACC ATC CGC CTC GAA GGC GGC GTC GAG	240
	Ser Ile Thr Ser Asp Gly Leu Thr Ile Arg Leu Glu Gly Gly Val Glu	
45	65 70 75 80	
	CCG AAC AAG CCG GTG CGC TAC AGC TAC ACG CGC CAG GCG CGC GGC AGT	288
	Pro Asn Lys Pro Val Arg Tyr Ser Tyr Thr Arg Gln Ala Arg Gly Ser	
	85 90 95	

	TGG TCG CTG AAC TGG CTG GTA CCG ATC GGC CAC GAG AAG CCC TCG AAC	336
	Trp Ser Leu Asn Trp Leu Val Pro Ile Gly His Glu Lys Pro Ser Asn	
	100 105 110	
5	ATC AAG GTG TTC ATC CAC GAA CTG AAC GCC GGC AAC CAG CTC AGC CAC	384
	Ile Lys Val Phe Ile His Glu Leu Asn Ala Gly Asn Gln Leu Ser His	
	115 120 125	
10	ATG TCG CCG ATC TAC ACC ATC GAG ATG GGC GAC GAG TTG CTG GCG AAG	432
	Met Ser Pro Ile Tyr Thr Ile Glu Met Gly Asp Glu Leu Leu Ala Lys	
	130 135 140	
15	CTG GCG CGC GAT GCC ACC TTC TTC GTC AGG GCG CAC GAG AGC AAC GAG	480
	Leu Ala Arg Asp Ala Thr Phe Phe Val Arg Ala His Glu Ser Asn Glu	
	145 150 155 160	
20	ATG CAG CCG ACG CTC GCC ATC AGC CAT GCC GGG GTC AGC GTG GTC ATG	528
	Met Gln Pro Thr Leu Ala Ile Ser His Ala Gly Val Ser Val Val Met	
	165 170 175	
25	GCC CAG ACC CAG CCG CGC CGG GAA AAG CGC TGG AGC GAA TGG GCC AGC	576
	Ala Gln Thr Gln Pro Arg Arg Glu Lys Arg Trp Ser Glu Trp Ala Ser	
	180 185 190	
30	GGC AAG GTG TTG TGC CTG CTC GAC CCG CTG GAC GGG GTC TAC AAC TAC	624
	Gly Lys Val Leu Cys Leu Leu Asp Pro Leu Asp Gly Val Tyr Asn Tyr	
	195 200 205	
35	CTC GCC CAG CAA CGC TGC AAC CTC GAC GAT ACC TGG GAA GGC AAG ATC	672
	Leu Ala Gln Gln Arg Cys Asn Leu Asp Asp Thr Trp Glu Gly Lys Ile	
	210 215 220	
40	TAC CGG GTG CTC GCC GGC AAC CCG GCG AAG CAT GAC CTG GAC ATC AAA	720
	Tyr Arg Val Leu Ala Gly Asn Pro Ala Lys His Asp Leu Asp Ile Lys	
	225 230 235 240	
45	CCC ACG GTC ATC AGT CAT CGC CTG CAC TTT CCC GAG GGC GGC AGC CTG	768
	Pro Thr Val Ile Ser His Arg Leu His Phe Pro Glu Gly Gly Ser Leu	
	245 250 255	
50	GCC GCG CTG ACC GCG CAC CAG GCT TGC CAC CTG CCG CTG GAG ACT TTC	816
	Ala Ala Leu Thr Ala His Gln Ala Cys His Leu Pro Leu Glu Thr Phe	
	260 265 270	
55	ACC CGT CAT CGC CAG CCG CGC GGC TGG GAA CAA CTG GAG CAG TGC GGC	864
	Thr Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln Cys Gly	
	275 280 285	
55	TAT CCG GTG CAG CGG CTG GTC GCC CTC TAC CTG GCG GCG CGG CTG TCG	912
	Tyr Pro Val Gln Arg Leu Val Ala Leu Tyr Leu Ala Ala Arg Leu Ser	
	290 295 300	
55	TGG AAC CAG GTC GAC CAG GTG ATC CGC AAC GCC CTG GCC AGC CCC GGC	960
	Trp Asn Gln Val Asp Gln Val Ile Arg Asn Ala Leu Ala Ser Pro Gly	
	305 310 315 320	

	AGC	GGC	GGC	GAC	CTG	GGC	GAA	GCG	ATC	CGC	GAG	CAG	CCG	GAG	CAG	GCC	1008
	Ser	Gly	Gly	Asp	Leu	Gly	Glu	Ala	Ile	Arg	Glu	Gln	Pro	Glu	Gln	Ala	
					325					330						335	
5	CGT	CTG	GCC	CTG	ACC	CTG	GCC	GCC	GCC	GAG	AGC	GAG	CGC	TTC	GTC	CGG	1056
	Arg	Leu	Ala	Leu	Thr	Leu	Ala	Ala	Ala	Glu	Ser	Glu	Arg	Phe	Val	Arg	
				340					345					350			
10	CAG	GGC	ACC	GGC	AAC	GAC	GAG	GCC	GGC	GCG	GCC	AAC	GCC	GAC	GTG	GTG	1104
	Gln	Gly	Thr	Gly	Asn	Asp	Glu	Ala	Gly	Ala	Ala	Asn	Ala	Asp	Val	Val	
			355					360					365				
15	AGC	CTG	ACC	TGC	CCG	GTC	GCC	GCC	GGT	GAA	TGC	GCG	GGC	CCG	GCG	GAC	1152
	Ser	Leu	Thr	Cys	Pro	Val	Ala	Ala	Gly	Glu	Cys	Ala	Gly	Pro	Ala	Asp	
		370					375					380					
20	AGC	GGC	GAC	GCC	CTG	CTG	GAG	CGC	AAC	TAT	CCC	ACT	GGC	GCG	GAG	TTC	1200
	Ser	Gly	Asp	Ala	Leu	Leu	Glu	Arg	Asn	Tyr	Pro	Thr	Gly	Ala	Glu	Phe	
	385					390					395					400	
25	CTC	GGC	GAC	GGC	GGC	GAC	GTC	AGC	TTC	AGC	ACC	CGC	GGC	ACG	CAG	AAC	1248
	Leu	Gly	Asp	Gly	Gly	Asp	Val	Ser	Phe	Ser	Thr	Arg	Gly	Thr	Gln	Asn	
				405					410						415		
30	TGG	ACG	GTG	GAG	CGG	CTG	CTC	CAG	GCG	CAC	CGC	CAA	CTG	GAG	GAG	CGC	1296
	Trp	Thr	Val	Glu	Arg	Leu	Leu	Gln	Ala	His	Arg	Gln	Leu	Glu	Glu	Arg	
				420					425					430			
35	GGC	TAT	GTG	TTC	GTC	GGC	TAC	CAC	GGC	ACC	TTC	CTC	GAA	GCG	GCG	CAA	1344
	Gly	Tyr	Val	Phe	Val	Gly	Tyr	His	Gly	Thr	Phe	Leu	Glu	Ala	Ala	Gln	
			435				440						445				
40	AGC	ATC	GTC	TTC	GGC	GGG	GTG	CGC	GCG	CGC	AGC	CAG	GAC	CTC	GAC	GCG	1392
	Ser	Ile	Val	Phe	Gly	Gly	Val	Arg	Ala	Arg	Ser	Gln	Asp	Leu	Asp	Ala	
		450					455					460					
45	ATC	TGG	CGC	GGT	TTC	TAT	ATC	GCC	GGC	GAT	CCG	GCG	CTG	GCC	TAC	GGC	1440
	Ile	Trp	Arg	Gly	Phe	Tyr	Ile	Ala	Gly	Asp	Pro	Ala	Leu	Ala	Tyr	Gly	
	465					470				475						480	
50	TAC	GCC	CAG	GAC	CAG	GAA	CCC	GAC	GCA	CGC	GGC	CGG	ATC	CGC	AAC	GGT	1488
	Tyr	Ala	Gln	Asp	Gln	Glu	Pro	Asp	Ala	Arg	Gly	Arg	Ile	Arg	Asn	Gly	
				485					490						495		
55	GCC	CTG	CTG	CGG	GTC	TAT	GTG	CCG	CGC	TCG	AGC	CTG	CCG	GGC	TTC	TAC	1536
	Ala	Leu	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser	Leu	Pro	Gly	Phe	Tyr	
				500					505					510			
60	CGC	ACC	AGC	CTG	ACC	CTG	GCC	GCG	CCG	GAG	GCG	GCG	GGC	GAG	GTC	GAA	1584
	Arg	Thr	Ser	Leu	Thr	Leu	Ala	Ala	Pro	Glu	Ala	Ala	Gly	Glu	Val	Glu	
			515				520					525					
65	CGG	CTG	ATC	GGC	CAT	CCG	CTG	CCG	CTG	CGC	CTG	GAC	GCC	ATC	ACC	GGC	1632
	Arg	Leu	Ile	Gly	His	Pro	Leu	Pro	Leu	Arg	Leu	Asp	Ala	Ile	Thr	Gly	
		530					535					540					
70	CCC	GAG	GAG	GAA	GGC	GGG	CGC	CTG	GAG	ACC	ATT	CTC	GGC	TGG	CCG	CTG	1680
	Pro	Glu	Glu	Glu	Gly	Gly	Arg	Leu	Glu	Thr	Ile	Leu	Gly	Trp	Pro	Leu	
	545					550					555					560	

GCC GAG CGC ACC GTG GTG ATT CCC TCG GCG ATC CCC ACC GAC CCG CGC 1728  
 Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp Pro Arg  
 565 570 575  
 5 AAC GTC GGC GGC GAC CTC GAC CCG TCC AGC ATC CCC GAC AAG GAA CAG 1776  
 Asn Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys Glu Gln  
 580 585 590  
 10 GCG ATC AGC GCC CTG CCG GAC TAC GCC AGC CAG CCC GGC AAA CCG CCG 1824  
 Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys Pro Pro  
 595 600 605  
 CGC GAG GAC CTG AAG 1839  
 15 Arg Glu Asp Leu Lys  
 610

### *Assessing Translocation to the Cytosol*

Any functional *Pseudomonas* polypeptide translocation domain can be used in the toxin conjugate of the invention. The functionality of a translocation domain can be tested as a function of the domain's ability to mediate and gain access to the cytosol (because access first requires binding to the cell, these assays are also useful to determine whether the SP domain is functioning, *i.e.*, binding to an NK-1 expressing cell). In one method, access to the cytosol is determined by detecting the physical presence of the toxin conjugate in the cytosol. For example, the toxin conjugate can be labeled with a composition that is detectable after the toxin conjugate gains entry inside a cell. Then, the cytosolic fraction is isolated (the endosomal compartment can also be separately isolated) and the amount of label in the cytosol fraction determined. Detecting label in the cytosol indicates that the translocation domain is functional and that the toxin conjugate has gained access to the cytosol.

### *Assessing ADP Ribosylation Activity*

Any functional *Pseudomonas* polypeptide translocation domain can be used in the toxin conjugate of the invention. The functionality of a domain III having ADP ribosylation activity can also be tested in a variety of ways. For example, cells can be seeded in tissue culture plates and exposed to the toxin conjugate. ADP ribosylation activity is determined as a function of inhibition of protein synthesis by, *e.g.*, monitoring the incorporation of <sup>3</sup>H-leucine.

### *Recombinant Expression of Pseudomonas Polypeptide Domains*

The functional *Pseudomonas* polypeptide translocation and ADP ribosylation domains can be expressed in any in vitro or in vivo recombinant system. In

one exemplary system, *Pseudomonas* polypeptide translocation and ADP ribosylation domains are designed as a single recombinant molecule based on the naturally expressed toxin (SEQ ID NO:6). In one exemplary design the recombinant molecule uses an initiating methionine in place of glycine at residue 280 (of SEQ ID NO:6), retains the cysteine of residue position 287, and eliminates the disulfide bond at residues 374 to 379; the resulting polypeptide is SEQ ID NO:1.

In one exemplary recombinant system, SEQ ID NO:1 (or equivalent thereof) is expressed into the periplasm of *E. coli* (using standard techniques, see, e.g., Sambrook). There, a large proportion of the toxin dimerizes by forming a disulfide bond (linking cysteines 287). Prior to conjugation, PE recombinant polypeptide preparations are treated with 2-mercaptoethanol and separated on a size exclusion chromatography column (using standard techniques). Any remaining dimers elute first, followed by monomer fractions, which are appropriately collected for further conjugation to SP-thio-nitrobenzoic acid derivatized peptide, as described below.

#### 15        *Substance P and the NK-1 Receptor*

An important pain-mediating peptide is the eleven amino acid long Substance P ("SP"). SP plays a central role in the transduction of second messenger signals from primary afferent nociceptive terminals to second-order neurons in the spinal cord (see, e.g., Lembeck (1981) supra). SP transduces a pain signal by interacting primarily with neurokinin-1 ("NK1") receptor-bearing cells in the brain and spinal chord (see, e.g., Abbadie (1996) supra; Seelig (1996) Biochemistry 35:4365-4374). One of the most studied SP circuits is the connection between primary afferent nociceptive dorsal root ganglion neurons and second order neurons in the spinal cord. This SP mediated signal is known to mediate pain signals. These second order neurons are essential links in the classical trisynaptic pathway of pain transmission from the periphery to the spinal cord to the thalamus to the somatosensory are of the cortex.

An SP peptide or variant thereof is within the scope of the invention if it is capable of binding to an NK-1 receptor expressed on a eukaryotic cell, such as a human cell (binding protocols for such determinations are well known in the art, see, e.g., Ciucci (1998) Br. J. Pharmacol. 125:393-401; Maguire (1998) Brain Res. 786:263-266; Quartara (1998) supra) and discussion below. SP peptides used in the toxin conjugates of the invention are further modified by the addition of a sulfhydryl group, e.g., a cysteine residue or equivalent, to the amino terminus of the peptide (for disulfide linked

conjugation, as discussed below). Additional of a sulfhydryl group to the amino terminus is important because the carboxy-terminus of the SP peptide must be amidated for the peptide to bind to the NK-1 receptor. SP peptides used in the invention can be amidated on their carboxy termini by any means, *e.g.*, by amidation of peptides which have been  
5 made synthetically or by the method set forth in Fisher (1996) *supra* (page 7342).

The invention provides a pharmaceutical composition and a method for the ablation of NK1 receptor expressing cells. Thus, the cell toxins of the invention can bind to (and kill) any NK1 receptor expressing cell. While pain mediating cells and neurons are the predominant cells expressing NK-1 receptors (*e.g.*, spinal cord dorsal horn  
10 neurons, see, *e.g.*, Basbaum (1999) *supra*), brain cells, see, *e.g.*, Saria (1999) *supra*; neostriatum cells through the axon collaterals of spiny projection neurons, see, *e.g.*, Galarraga (1999) *supra*), a variety of other normal or abnormal (*e.g.*, tumor) cells also express NK-1 receptor and thus can be killed practicing this invention. Thus, the cell toxins and methods of the invention can be used to treat a variety of different conditions  
15 or to modify a variety of different physiologic mechanisms. For example, spinal NK1 receptors modulate autonomic reflexes, including the micturition reflex. In the peripheral nervous system, NK1 receptors are widely expressed in the respiratory, genitourinary and gastrointestinal tracts and are also expressed by several types of inflammatory and immune cells. In the cardiovascular system, NK1 receptors mediate endothelium-  
20 dependent vasodilation and plasma protein extravasation. At respiratory level, NK1 receptors mediate neurogenic inflammation which is especially evident upon exposure of the airways to irritants. In the carotid body, NK1 receptors mediate the ventilatory response to hypoxia. In the gastrointestinal system, NK1 receptors mediate smooth muscle contraction, regulate water and ion secretion and mediate neuro-neuronal  
25 communication. In the genitourinary tract, NK1 receptors are widely distributed in the renal pelvis, ureter, urinary bladder and urethra and mediate smooth muscle contraction and inflammation in response to noxious stimuli. NK1 receptors antagonists, including toxins that can ablate NK-1 receptor expression cells, may have several therapeutic applications at central and peripheral level. In the central nervous system, NK1 receptor  
30 ablation toxins could be used to produce analgesia, as antiemetics and for treatment of certain forms of urinary incontinence due to detrusor hyperreflexia. In the peripheral nervous system, toxins of the invention could be used in several inflammatory diseases including arthritis, inflammatory bowel diseases and cystitis (Quartara (1998) *supra*). Further uses of the toxins and methods of the invention are suggested by, *e.g.*, Al, et al.,

who show that SP and its receptor are expressed in human peripheral blood-isolated lymphocytes (Lai (1998) J. Neuroimmunol. 86:80-86). Using cultured rabbit osteoclasts, Mori et al. found that SP possibly stimulates the bone remodeling by osteoclasts (Mori (1999) Biochem. Biophys. Res. Commun. 262:418-422). SP present in bronchial nerve  
5 fibers can induce relaxation of rat bronchial smooth muscle (Bodelsson (1999) Respiration 66:355-359). SP has anxiolytic-like effects when administered into the nucleus basalis of the rat ventral pallidum (Nikolaus (1999) Neuroreport 10:2293-2296). Baraniuk, et al. showed that a nociceptive nerve efferent axon response may lead to glandular exocytosis through actions on submucosal gland NK-1 receptors (Baraniuk  
10 (1999) Am. J. Respir. Crit. Care Med. 160:655-662). Maubach, et al. showed that a SP receptor antagonist had antidepressant efficacy (Maubach (1999) Curr. Opin. Chem. Biol. 3:481-488). Santoni, et al. speculates that SP plays a major role in the regulation of the interaction between immune and nervous systems. Santoni (1999) J. Neuroimmunol. 93:15-25).

15                   The conjugates may also be used in the treatment of neurological dysfunctions of the basal ganglia by targeting cholinergic interneurons that express SP (e.g. Parkinsons Disease, see, e.g., Kaneko Science 289:633-637, 2000). In such a use, the composition is typically administered directly to the brain.

## 20   **Disulfide Linked Cell Toxin Conjugates**

The invention provides disulfide linked cell toxin conjugates comprising a modified SP peptide and a modified PE translocation domain linked to a PE ADP-ribosylation domain. Chemical conjugation is advantageous over synthesis by, e.g., entirely recombinant techniques, because a better defined homogenous product is  
25 obtained (recombinant expression *in vivo*, e.g., mammalian cells or bacteria, in contrast, commonly results in mixed products due to posttranslational modification, degradation, and the like). In the present invention, conjugates are made by "disulfide exchange." To ensure that the ratio of SP to PE in each conjugate molecule is 1:1, the SP peptide and the *Pseudomonas* exotoxin component of the toxin conjugate each have only one reactive  
30 sulfhydryl group. The sulfhydryl group for disulfide exchange can be in the form of a cysteine (or equivalent, see above) residue.

To make the conjugate, the SP-cysteine (or equivalent) (e.g., SEQ ID NO:4), generated by solid phase synthesis, initially purified, and amidated. It next

reacted with dithio-bis (2-nitro)-benzoic acid (DTNB). This reaction yields a thio-nitrobenzoic acid derivatized SP peptide ("SP-TNB") and a thionitro benzoate group.

In one exemplary protocol, SP-TNB is added to the *Pseudomonas* exotoxin component (having only one reactive sulfhydryl group) in a 8:1 molar ratio for an overnight incubation at 4C. Progress of the reaction is monitored, *e.g.*, by measuring absorbance at OD 412 nm. SP-TNB can be purified, *e.g.*, by HPLC. The SP-PE pharmaceuticals of the invention have less than 2% thionitro benzoate groups.

SP-TNB is dissolved in 20% DMSO (*e.g.*, 2 mg SP-TNB in 20 microliters DMSO). Then 1.0 milliliter of 0.2 molar Na-phosphate is added (pH 7.0). The conjugation mixture is applied to gel filtration column (*e.g.*, G-25) to remove unreacted SP-TNB and eluted. The mixture was further purified by HPLC gel filtration to remove unreacted PE polypeptide. Fractions are collected and analyzed by Western blot to confirm the presence of *Pseudomonas* exotoxin domain (by reaction with monoclonal anti-PE antibody) and monoclonal anti-SP antibody (directed to the amidated carboxy terminus of the SP). The presence of a disulfide linkage is confirmed by reduction (*e.g.*, with 2-ME or dithiothreitol) followed by gel electrophoresis (*e.g.*, SDS-PAGE) and Western blot analysis with the above referenced monoclonal antibodies. Fractions containing one to one (1:1) PE to SP molar relationship conjugates are retained and stored, *e.g.*, at -80 C.

## 20 Formulation and Administration Pharmaceuticals

The cell toxin conjugates of the invention are formulated as pharmaceuticals to be used in the methods of the invention to treat pain, particularly chronic pain. These pharmaceuticals can be administered by any means in any appropriate formulation. Routine means to determine drug regimens and formulations to practice the methods of the invention are well described in the patent and scientific literature, and some illustrative examples are set forth below. For example, details on techniques for formulation and administration are well described in the scientific and patent literature, see, *e.g.*, the latest edition of Remington's Pharmaceutical Sciences, Maack Publishing Co, Easton PA.

The pharmaceutical composition of the invention is administered such that the cell toxin conjugate is anatomically approximate to an NK-1 receptor bearing cell, *e.g.*, a nerve, including, *e.g.*, epineurium or perineurium, tissue surrounding nerve ganglia, nerve sheathes, nerve linings, or meninges, *e.g.*, the pia mater, or arachnoid or



dura membranes. The pharmaceutical composition can be administered into the subarachnoid space. The pharmaceutical composition can be administered in or approximate to joints for, *e.g.*, the treatment of chronic pain associated with arthritis.

The pharmaceutical composition can be administered intrathecally (*i.e.*,  
5 into the CSF in the subarachnoid space), where the concentration of cell toxin conjugate in the pharmaceutically acceptable excipient can be between about 0.5 to about 50 mL of a formulation at dosages equivalent to about 0.2 to about 0.6 mg/kg, or, about 0.1 to about 1.0 mg/kg, or, about 0.2 to  $10^3$  nanograms per microliter, depending on a variety of conditions, as described below. The delivery can be through implanted or external  
10 intrathecal or epidural pumps, see, *e.g.*, Hassenbusch (1999) Oncology 13(5 Suppl 2):63-7.

Aqueous suspensions of the invention can also include any excipients or admixture suitable for the manufacture of aqueous suspensions. The aqueous suspension can also contain one or more preservatives, such as ethyl or n-propyl p-hydroxybenzoate.  
15 The aqueous suspension can be adjusted for osmolarity. The aqueous solution can be adjusted to promote the stability of the vector for lyophilization. For example, a cryoprotectant solution that can significantly maintain stability after freeze-thaw cycles.

The pharmaceutical formulations of the invention can be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric,  
20 acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5, that is combined with the appropriate aqueous buffer prior to use.

25 After a pharmaceutical comprising a cell toxin conjugate of the invention has been formulated in an acceptable carrier/ excipient it can be placed in an appropriate container, *e.g.*, as a kit, and labeled for treatment of the indicated condition. For administration of the pharmaceutical compositions of the invention, such labeling would include, *e.g.*, instructions concerning the amount, frequency and method of  
30 administration. These instructions can also be part of a kit.

The cell toxin conjugates of the invention can also be formulated as cationic lipid-nucleic acid compositions for administration in a variety of ways. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, *e.g.*, the latest edition of "Remington's Pharmaceutical Sciences"

(Maack Publishing Co, Easton PA). See also, Lasic and Templeton (1996) Adv. Drug Deliv. Rev. 20: 221-266 and references cited therein. The ratios of each component in the cationic lipid-nucleic acid complexes, final concentrations, buffer solutions, and the like can be readily optimized by the skilled artisan, taking into consideration the mode of delivery (*i.e.*, intrathecal, epidural, intra-articular, direct injection into brain or spinal cord parenchyma), the anatomical site of delivery, any existent conditions or diseases, the condition and age of the patient, and the like. Methods of producing cationic liposomes are known in the art (see *e.g.*, Liposome Technology (CFC Press, NY 1984); Liposomes, Ortro (Marcel Schher, 1987).

10        *Determining Dosing Regimens*

The pharmaceutical formulations of the invention can be administered in a variety of unit dosage forms, depending upon the particular condition or disease, the degree of chronic pain, the general medical condition of each patient, the method of administration, and the like. Details on dosages are well described in the scientific and patent literature, see, *e.g.*, the latest edition of Remington's Pharmaceutical Sciences, Maack Publishing Co, Easton PA.

The exact amount and concentration of cell toxin conjugate and the amount of formulation in a given dose, or the "therapeutically effective dose" is determined by the clinician, as discussed above. The dosage schedule, *i.e.*, the "dosing regimen," will depend upon a variety of factors, including, *e.g.*, the amount of chronic pain present, the duration of the pain, the stage and severity of the disease or condition associated with the chronic pain (if any), and the general state of the patient's health, physical status, age and the like. The state of the art allows the clinician to determine the dosage regimen for each individual patient and, if appropriate, concurrent disease or condition treated; see, *e.g.* Selvaggi (1993) J. Immunother. 13:201-207

One typical dosage is between about 0.5 to about 50 mL of a formulation at dosages equivalent to about 0.2 to about 0.6 mg/kg daily (however, the dosage can be adjusted, as described below, from about 0.01 to about 2.0 mg/kg). Dosage levels and frequency of administration (daily for several days, every other day, etc.) are based on objective and subjective criteria, as discussed herein. Any dosage can be used as required and tolerated by the patient. Furthermore, the exact concentration of toxin conjugate, the amount of formulation, and the frequency of administration can be adjusted depending on the levels of SP-PE measured in the CSF after an initial administration. Means to sample

CSF or other fluid or tissue samples and detect and quantitate levels of SP-PE are well known in the art (see Example 1, below).

#### *Routes of Administration*

The pharmaceutical compositions of the invention can be administered by any means known in the art to any anatomical space, *e.g.*, intrathecally, subdurally, direct injection in brain or spinal cord parenchyma. If treating a cancer that expresses a receptor that binds to SP (*e.g.* NK-1 receptor), the pharmaceutical can also be administered, *e.g.*, intravenously or directly into the tumor. The pharmaceutical composition of the invention can be administered to any cell which expresses NK-1 receptors, including, but not limited to epineurium cells, perineurium cells, nerve ganglia, nerve sheathes, nerve linings, meninges, pia mater cells, arachnoid membrane cells, dura membrane cells, cells lining a joint or brain or spinal cord parenchymal cells. For example, the pharmaceutical composition can be administered intrathecally or epidurally in a pharmaceutically acceptable excipient. Means to administer solutions into all of these anatomical compartments are well known in the art, see, *e.g.*, the subarachnoid space, *i.e.*, intrathecally, into the CSF, see, *e.g.*, Oyama, T., U.S. Patent No. 4,313,937; discussing intrathecal pumps, see, *e.g.*, Nance (1999) Phys. Med. Rehabil. Clin. N. Am. 10:385-401; Anderson (1999) Neurosurgery 44:289-300.

The cell toxin of the invention can be administered by single or multiple or continuous infusion (*e.g.*, by pumps, internal or external) into the intrathecal or epidural space, or directly into brain or spinal cord parenchyma, depending on the dosage and frequency as required and tolerated by the patient.

#### **Kits**

The invention provides a kit for the treatment of chronic pain in a human which includes a pharmaceutical composition of the invention. The kit can contain instructional material teaching preferred indications, dosages and schedules of administration, and the like.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

### EXAMPLES

The following example is offered to illustrate, but not to limit the claimed invention.

**Example 1: Substance P-Pseudomonas Exotoxin Disulfide Linked Conjugate Selectively and Potently Kills Neurokinin-1 Receptor Expressing Cells**

The following example details a study which demonstrates that compositions and methods of the invention can be practiced to ablate NK-1 receptor expressing cells. Specifically, this study demonstrates that CHO cells stably transfected with and expressing NK-1 receptors, but not NK-2 or NK-3 receptors, can be killed by the SP-PE cell toxin conjugate of the invention.

A disulfide linked SP-PE cell toxin was made as described above. Specifically, an synthetic SP peptide (SEQ ID NO:4) was carboxy-terminal amidated prior to conjugation using standard techniques.

The carboxy-terminal amidated, N-terminal thio-nitrobenzoic acid derivatized SP peptide was reacted with a recombinant PE polypeptide having an N-terminal domain with a sequence as set forth in SEQ ID NO:1 and a carboxy-terminal domain (the translocation domain) with a sequence as set forth in SEQ ID NO:2 (the ADP-ribosylation domain). The cell toxin conjugate was purified and analyzed for the presence of disulfide linkage, SP peptide and PE domains as described above. The preparation was substantially pure of free thionitrobenzoate groups.

CHO cells were stably transfected with either NK-1, NK-2 or NK-3 receptor encoding nucleic acid sequences (see, *e.g.*, Maggi (1997) Trends Pharmacol. Sci. 18:351-355; Tian (1996) J. Neurochem. 67:1191-1199) using conventional techniques. Cell surface expression of each respective receptor was confirmed by reaction with receptor specific antibodies (see, *e.g.*, Dery (1997) J. Neuroimmunol. 76:1-9); Arkinstall (1995) FEBS Letters 375:183-187.

NK-1, NK-2 or NK-3 receptor-expressing CHO transformant cell cultures were grown to 90% confluence. The cultures were exposed to the SP-PE cell toxin for various times, including 1.5 minutes, 3 hours, and 24 hours. After exposure, cells were washed and allowed to proliferate for a further 24 or 48 hours. At these times media and any non-adherent cells (*i.e.*, dead cells) were removed and the cultures fixed and stained with toluidine/methylene blue in ethanol. These stained cultures were photographed and the images on the slides were digitized by scanning with a digital camera. The average

number of live/ dead cells per plate was calculated by using the “analyze” and “histogram” functions in ADOBE™ photoshop program using standard techniques.

The SP-PE toxin was very specific for NK-1 receptor-expressing cells, which were killed with an IC<sub>50</sub> of 2 ng/ml ( $5 \times 10^{-11}$  M). No killing was seen when NK-1 receptor-expressing cells were incubated with unconjugated PE domains. No killing was seen when NK-2 or NK-3 receptor-expressing cells were exposed to SP-PE toxin.

Toxicity to NK-1 receptor expressing cells was blocked by the addition of excess free SP or by treating the toxin conjugate with an anti-SP antibody. Cytotoxicity occurred with exposure times to toxin as short as two minutes (lethality assessed at 24 hours after exposure).

The specificity for SP-PE toxin for NK-1 receptor-expressing cells was confirmed by incubating the panel of stably transfected cells with tritiated leucine (<sup>3</sup>H-leucine) and SP-PE toxin (made as described in Example 1). Viable cells incorporate the amino acid leucine to synthesize polypeptides. Dead or dying cells do not synthesize polypeptides and do not incorporate the <sup>3</sup>H-leucine. Figure 1 shows a schematic summary of data of experiments testing the ability of the SP-PE conjugate toxin of the invention to kill CHO cells stably transfected with and expressing NK-1 receptors (Fig. 1A), NK-2 receptors (Fig. 1B), and NK-3 receptors (Fig. 1C).

The SP-PE toxin only compromised the viability of NK-1 receptor-expressing cells. The viability of NK-1 and NK-3 receptor expressing cells was the same as the (negative) control. As a (negative) control, in place of SP-PE toxin, the cells were exposed to the PE domain alone (lacking the receptor ligand SP) (designated “PE35” in Fig. 1). PE domain alone did not compromise the viability of any of the transfected cells.

These data demonstrate that the SP-PE toxin conjugates of the invention specifically ablate NK-1 receptor expressing cells.

**Example 2:** SP-Pseudomonas Exotoxin Disulfide Linked Conjugate Kills NK-1 - Expressing Cells in Rat Spinal Column Dorsal Horn Cells In Vivo

The following example details a study which demonstrates that compositions and methods of the invention can be practiced to ablate NK-1 receptor expressing cells in the dorsal horn of the spinal column *in vivo*. Specifically, this art-recognized animal model for pain therapy demonstrates that the SP-PE toxin of the invention administered *in vivo* via intrathecal injection selectively and potently killed dorsal horn NK-1 receptor expressing cells. The toxin conjugate of the invention was

extremely effective deleting NK-1 receptor expressing cells from the dorsal horn of the spinal cord and NK-1 receptor expressing cells from the striatum.

Male Sprague-Dawley rats were used in all experiments. All procedures and experimental protocols were approved by an NIH Animal Care and Use Committee and are in accordance with the guidelines of the International Association for the Study of Pain (Zimmermann (1983) Pain 16:109-110). Animals were anesthetized and the SP-PE toxin of the invention (as described in Example 1, above) administered by intrathecal infusion as described by Benoliel (1999) Pain 79:243-253, at a dose of 20  $\mu$ l containing a concentration of 25 nanograms per  $\mu$ l.

Tissue preparation and immunocytochemistry were performed as by Benoliel (1999) *supra*. Tissue sections were harvested eight days after intrathecal treatment with SP-PE toxin (or saline as a negative control). Dorsal horn tissue sections of the spinal cord were stained with antibodies for NK-1 receptor. Sections from animals treated with SP-PE toxin clearly showed significant ablation of SP receptor-expressing cells (loss of anti-NK-1 receptor antibody reactivity) in the dorsal horn of the rat spinal column. Animals treated with saline only showed normal SP receptor-expressing cell staining pattern, i.e., no ablation. The saline control showed strong staining for an antibody reactive NK-1 receptor.

These data demonstrate that the SP-PE toxins of the invention ablate NK-1 receptor expressing cells in the dorsal horn of the spinal column *in vivo*.

**Example 3: SP-Pseudomonas Exotoxin Disulfide Linked Conjugate Administered In Vivo Decreased Pain Sensation in a Heat Hyperalgesia Test**

The following example details a study with an art-recognized animal (rat) model for investigating treatments for pain which shows that the SP-PE compositions of the invention can be used and methods of the invention can be practiced to treat pain.

All animal procedures and intrathecal toxin administrations were as described above (Example 2), as in Benoliel (1999) *supra*. The SP-PE toxin used was prepared as described in Example 1, above. Heat sensitivity was assayed with a withdrawal latency test as described by Iadarola (1988) Brain Res. 455:205-212, see also Benoliel (1999) *supra*. Sensitivity to nociceptive thermal stimulation was tested in unrestrained rats with a radiant heat stimulus as described. Briefly, the rat is placed on an elevated glass plate, with a clear plastic cage inverted over the animal. After 5 min habituation to the enclosure, a projector lamp in a conical housing is positioned under the

fore or hind paws or tail. The light emerges from an opening in the conical housing light. The latency is recorded automatically when paw or tail movement interrupts the readings of a photocell in the lamp housing. Four rats were tested with toxin and four rats were controls. Assays were conducted 20 days after toxin treatment.

5                   Figure 2 shows a schematic summary of data of experiments testing the ability of the SP-PE conjugate toxin of the invention to treat pain. Administration of SP-PE toxin significantly increased paw withdrawal latency as compared to control (saline only administered). The "normal" or saline control latency was 8 seconds while the "pain desensitized" toxin treated animal had a withdrawal latency of between 14 and 16  
10 seconds. Similar effects are also observed at 8 days following SP-PE administration.

To further evaluate long-term effects and selectivity following SP-PE treatment, control and treated animals were analyzed for withdrawal latency. Heat withdrawal latency was tested as described in Example 2.

The ability of SP-PE to selectively block thermal heat pain in rats at a  
15 target region was tested 46 days after intrathecal injection of about 15 picomoles of SP-PE (Figure 3), which was infused slowly at a rate of about 1  $\mu$ l per minute (dose of 20  $\mu$ l containing a concentration of 25 nanograms per  $\mu$ l). In this study, the conjugate was administered to the region of the cord that affects pain perception in the tail. The results show segmental selectivity of SP-PE applied at sacral spinal cord and demonstrate that  
20 the effect of SP-PE treatment can be localized to control the site of action, even though the injection is made into a fluid-filled space.

To demonstrate that administration of SP-PE to rats attenuates a symptom of chronic pain, hyperalgesia, a rat thermal hyperalgesia model was used. This method measures cutaneous hyperalgesia to thermal stimulation in unrestrained animals, and was  
25 performed essentially as described by Hargreaves (1988) Pain 32:77-88. Briefly, after administration of expression vector, baseline thermal hyperalgesia is assessed by paw withdrawal latency to thermal stimulus. Inflammation is then induced with unilateral injection of 6 mg carrageenan (type IV Sigma C-3889) in volume of 0.15 mL PBS into a hindpaw of a 200-300 g male rat. Paw withdrawal latency to thermal stimulus is again  
30 measured on both the inflamed and uninflamed paws.

The ability of SP-PE to block acute thermal pain in the foot and to block thermal hyperalgesia in the carrageenan model of hind paw inflammation was tested at 46 days following treatment (Figure 4). The data obtained from the animals before induction

of inflammation, (the pre-inflamed data) show that 46 days after intrathecal injection of 15 picomoles SP-PE, the treated animals showed an increased withdrawal latency. When tested in the inflammation model system, the treated animals also showed blocking of thermal hyperalgesia, which incates that the SP-PE will also be useful in chronic pain syndromes.

Treatment with SP-PE also blocks mechanical pain, *i.e.*, a mild pinch with a toothed forceps. This effect occurs in a segmental fashion. Thus, if the infusion occurs around the hindpaw region of the spinal cord, the loss of pinch sensitivity is seen in the tail, hind paws, and part of the lower trunk, but not in the upper half of the body.

This art-recognized animal (rat) model for investigating treatments for pain clearly demonstrate that the SP-PE toxin conjugates of the invention are effective in the treatment of pain *in vivo*.

**Example 4: Long term effects on other neurotransmitter systems following SP-PE treatment**

This example shows that other neurotransmitter systems do not undergo long term compensatory rearrangements following treatment with SP-PE.

Compensatory rearrangments of the nervous system might occur after removal of a cell population, which, in turn could alter the therapeutic effects of administration of SP-PE. To evaluate the effects of SP-PE treatment on other neurotransmitter systems, immunocytochemistry for calcitonin gene-related peptide (CGRP) and tyrosine hydroxylase (TH) was performed on dorsal horn tissue samples obtained from control and SP-PE treated animals at 20 days post treatment. Tissue samples were prepared as in Example 2 and sections were stained with antibodies specific for CGRP or TH.

The distribution of CGRP, which is produced by primary afferent neurons, was analyzed 20 days following administration of 15 picomoles SP-PE. The results showed that the distribution and amount of CGRP observed in tissue samples in the treated animals appeared to be equivalent to that of the control.

Tyrosine hydroxylase is involved in the production of the biogenic amines, dopamine, norepinephrine (the transmitter in sympathetic nervous sytem fibers), and epinephrine. These neurotransmitters have been implicated in rearrangements in the dorsal root ganglion upon nerve injury. The result of the immunocytochemistry analysis at 20 days post treatment showed no consistent effects on TH innervation in treated



animals, which is likely due to the fact that only a small population of cells is being removed from the dorsal spinal cord.

These experiments demonstrate that administration of SP-PE does not result in compensatory rearrangement. The magnitude of the decrease in sensitivity to pain in SP-PE-treated animals was also equivalent at 70 days after administration of the conjugate to that observed at 20-46 days post-treatment. Further, animals at over 70 days post-treatment exhibited normal locomotion and there was no evidence of autotomy.

**Example 5: Intrastriatal Administration of SP-PE**

The following example shows that intrastriatal administration of SP-PE results in deletion of NK-1-expressing striatal neurons.

Rats administered SP-PE intrastriatally received a total dose of 25 ng of the conjugate. Animals were anesthetized and a one  $\mu$ l injection of conjugate was made over about 1 minute into the striatum. The rats were then assessed for apomorphine-induced turning behavior and neuronal toxicity.

A unilateral intrastriatal injection of SP-PE did not produce an appreciable alteration in the rats locomotor activity, posture or gait. However, when challenged with a systemically administered apomorphine, the rats displayed a strong contralateral turning behavior. Apomorphine also produced hyper-locomotion.

Immunocytochemical analysis also showed that the same dose that produced the contralateral turning behavior also produced a marked decrease in NK1 immunoreactive neurons in the rat striatum. The baseline NK1 immunoreactivity was most dense in the dorsal and lateral striatum and was associated with the dendrites of the neurons, although in the ventral striatum and olfactory tubercle, neuronal cell bodies were clearly observed. Previous research has shown that the NK1 positive striatal neurons are the medium spiny cholinergic interneurons. Microinjection of 25 ng of SP-PE (~0.7 picomoles) produced a macroscopically noticeable, unilateral zone of NK1 receptor loss in striatum, in comparison to the contralateral side of the same animal. The neuropil on the non-injected side contained a dense amount of NK1-immunopositive dendrites and cell bodies. These were eliminated from the injected zone on the other side.

The direct intrastriatal injections also provided an opportunity to assess potential toxic effects on non-receptor expressing cells exposed directly to the SP-PE conjugate. The integrity of other neural elements was assessed in two ways. First, the

NK1 stained sections were immunocytochemically counter-stained for neurofilament protein, which localizes to the cortico-spinal fiber bundles. The bundles were not affected by SP-PE even though they are in the center of the zone of medium spiny interneuron denervation. Second, standard histological stains of paraffin embedded thin sections were used to assess pathological changes. The Sections that included the cannula tract were stained with hematoxylin-eosin or luxol-fast blue. If a large amount of non-specific cell death had occurred a widespread loss of neuronal perikarya and a large microglial infiltration surrounding the tip of the cannula could be expected. Neither effect was observed; the appearance of the injected striatum was indistinguishable from either surrounding tissue or the contralateral side in which the NK1 receptor bearing cells were unaffected.

Thus, intrastriatal administration of SP-PE produced behavioral effects (contraversive turning with a apomorphine challenge, 3mg/kg intraperitoneal injection) and selective loss of SPR expressing cholinergic interneurons with no concurrent loss of Mu-opioid receptors.

**Example 6: SP-Pseudomonas Exotoxin Disulfide Linked Conjugate Administered To Patients with Chronic Pain**

The following example details the treatment of chronic pain in patients using the SP-PE compositions, *e.g.*, the pharmaceuticals, of the inventions.

As substance P (SP) peptide is a known mediator of chronic pain (as a ligand for the NK-1 receptor), the SP-PE pharmaceuticals of the invention can be efficaciously administered to virtually any patient having chronic pain. Means to diagnose and assess chronic pain is discussed in detail, above. As noted above, while chronic pain is diagnosed and treatments are assessed using both objective and subjective criteria, a diagnosis of a particular pathologic process (which is usually also chronic) known to produce or be associated with chronic pain is helpful to the clinician in determining when to administer the pharmaceutical compositions of the invention. Such conditions are well characterized and include, *e.g.*, chronic pain syndrome, arthralgia, osteoarthritis and rheumatoid arthritis, causalgia, hyperpathia, neuralgia, neuritis, radiculalgia, fibromyalgia, orofacial pain and temporomandibular disorders, reflex sympathetic dystrophy, chronic back pain, certain cancers, and the like.

In one exemplary protocol, patients diagnosed with chronic pain are treated with an SP-PE pharmaceutical compositions suitable for intrathecal

administration. While the dosage schedule, *i.e.*, the “dosing regimen,” will depend upon a variety of factors, including, *e.g.*, the amount of chronic pain present, the duration of the pain, the stage and severity of the disease or condition associated with the chronic pain (if any), and the general state of the patient’s health, physical status, age and the like, one  
5 typical dosage is between about 0.5 to about 50 mL of a formulation at dosages equivalent to about 0.2 to about 0.6 mg/kg daily for five days. This is administered by an internal or external intrathecal infusion pump. These pumps, while typically used for administration of opioids, can be used to administer the pharmaceuticals of the present invention; see, *e.g.*, Likar (1999) *Arzneimittelforschung* 49:489-493; Valentino (1998) *J.*  
10 *Neurosci. Nurs.* 30:233-239, 243-234.

Dosage levels and frequency of administration are continuously adjusted based on objective and subjective criteria, as discussed herein. Any dosage can be used as required and tolerated by the patient. Furthermore, the exact concentration of toxin conjugate, the amount of formulation, and the frequency of administration can be adjusted  
15 depending on the levels of SP-PE measured in the CSF after an initial administration. Means to sample CSF or other fluid or tissue samples and detect and quantitate levels of SP-PE are discussed above.

WHAT IS CLAIMED IS:

1. A method of making a cell toxin comprising  
reacting a polypeptide comprising a *Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain, wherein the *Pseudomonas* exotoxin translocation domain comprises at least one reactive sulfhydryl group, with a substance P peptide comprising one additional cysteine residue at its amino terminal end, wherein the cysteine sulfhydryl group is disulfide linked to a di-thiobis (2-nitro)-benzoic acid group, such that after the reaction a disulfide bond is formed between the exotoxin polypeptide and the substance P and a thionitrobenzoate group is released, and  
10 purifying the substance P-*Pseudomonas* exotoxin disulfide linked conjugate from the released thionitrobenzoate group such that the purified conjugate is substantially free of thionitrobenzoate groups.
2. The method of claim 1, wherein the *Pseudomonas* exotoxin translocation domain sulfhydryl group is located within ten amino acid residues of the amino terminus.  
15
3. The method of claim 1, wherein the *Pseudomonas* exotoxin translocation domain sulfhydryl group is located at the amino terminus.
- 20 4. The method of claim 1, wherein the *Pseudomonas* exotoxin translocation domain sulfhydryl group is a cysteine residue.
5. The method of claim 1, wherein the *Pseudomonas* exotoxin translocation domain is covalently linked to the *Pseudomonas* exotoxin ADP-ribosylation domain.  
25
6. The method of claim 5, wherein the covalent linkage between the *Pseudomonas* exotoxin translocation domain and the *Pseudomonas* exotoxin ADP-ribosylation domain is a peptide bond.
- 30 7. The method of claim 1, wherein the *Pseudomonas* exotoxin translocation domain comprises an amino acid sequence as set forth in SEQ ID NO:1 and the *Pseudomonas* exotoxin ADP-ribosylation domain comprises an amino acid sequence as set forth in SEQ ID NO:2.

8. A pharmaceutical composition for the ablation of NK1 receptor expressing cells comprising a cell toxin and a pharmaceutically acceptable excipient,  
wherein the cell toxin is a substance P-*Pseudomonas* exotoxin disulfide linked conjugate made by a process comprising the following steps:
- 5 reacting a polypeptide comprising a *Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain, wherein the *Pseudomonas* exotoxin translocation domain comprises at least one reactive sulfhydryl group, with a substance P peptide comprising one additional cysteine residue at its amino terminal end, wherein the cysteine sulfhydryl group is disulfide linked to a di-thiobis (2-nitro)-benzoic acid group, such that after the reaction a disulfide bond is formed between  
10 the exotoxin polypeptide and the substance P and a thionitrobenzoate group is released, and
- purifying the substance P-*Pseudomonas* exotoxin disulfide linked conjugate from the released thionitrobenzoate group such that the purified conjugate is  
15 substantially free of thionitrobenzoate groups.
9. The pharmaceutical composition of claim 8, wherein the *Pseudomonas* exotoxin translocation domain sulfhydryl group is located within ten amino acid residues of the amino terminus.
- 20
10. The pharmaceutical composition of claim 8, wherein the *Pseudomonas* exotoxin translocation domain sulfhydryl group is located at the amino terminus.
11. The pharmaceutical composition of claim 8, wherein the *Pseudomonas* exotoxin  
25 translocation domain sulfhydryl group is a cysteine residue.
12. The pharmaceutical composition of claim 8, wherein the *Pseudomonas* exotoxin translocation domain is covalently linked to the *Pseudomonas* exotoxin ADP-ribosylation domain.
- 30
13. The pharmaceutical composition of claim 12, wherein the covalent linkage between the *Pseudomonas* exotoxin translocation domain and the *Pseudomonas* exotoxin ADP-ribosylation domain is a peptide bond.

14. The pharmaceutical composition of claim 8, wherein the *Pseudomonas* exotoxin translocation domain comprises an amino acid sequence as set forth in SEQ ID NO:1 and the *Pseudomonas* exotoxin ADP-ribosylation domain comprises an amino acid sequence as set forth in SEQ ID NO:2.

5

15. The pharmaceutical composition of claim 8, wherein the cell toxin and pharmaceutically acceptable excipient are suitable for administration intrathecally, subdurally or directly into the brain parenchyma.

10 16. A method for ablating an NK1 receptor expressing cell in a patient comprising administering a cell toxin in a pharmaceutically acceptable excipient in an amount sufficient to ablate an NK1 receptor expressing cell,

wherein the cell toxin is a substance P-*Pseudomonas* exotoxin disulfide linked conjugate made by a process comprising the following steps:

15 reacting a polypeptide comprising a *Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain, wherein the *Pseudomonas* exotoxin translocation domain comprises at least one reactive sulfhydryl group, with a substance P peptide comprising one additional cysteine residue at its amino terminal end, wherein the cysteine sulfhydryl group is disulfide linked to a di-thiobis (2-nitro)-benzoic acid group, such that after the reaction a disulfide bond is formed between  
20 the exotoxin polypeptide and the substance P and a thionitrobenzoate group is released, and

purifying the substance P-*Pseudomonas* exotoxin disulfide linked conjugate from the released thionitrobenzoate group such that the purified conjugate is  
25 substantially free of thionitrobenzoate groups.

17. The method of claim 16, wherein the ablated NK1 receptor expressing cell is a dorsal horn cell, a stratum cell or a brain parenchyma cell.

30 18. A method of treating chronic pain without significantly affecting basal nociceptive responses comprising administering a cell toxin in a pharmaceutically acceptable excipient in an amount sufficient to treat chronic pain without significantly affecting basal nociceptive responses,

wherein the cell toxin is a substance P-*Pseudomonas* exotoxin disulfide linked conjugate made by a process comprising the following steps:


- reacting a polypeptide comprising a *Pseudomonas* exotoxin translocation domain linked to a *Pseudomonas* exotoxin ADP-ribosylation domain, wherein the
- 5 *Pseudomonas* exotoxin translocation domain comprises at least one reactive sulfhydryl group, with a substance P peptide comprising one additional cysteine residue at its amino terminal end, wherein the cysteine sulfhydryl group is disulfide linked to a di-thiobis (2-nitro)-benzoic acid group, such that after the reaction a disulfide bond is formed between the exotoxin polypeptide and the substance P and a thionitrobenzoate group is released,
- 10 and

purifying the substance P-*Pseudomonas* exotoxin disulfide linked conjugate from the released thionitrobenzoate group such that the purified conjugate is substantially free of thionitrobenzoate groups.

- 15 19. The method of claim 18, wherein cell toxin is administered to epineurium cells, perineurium cells, nerve ganglia, nerve sheathes, nerve linings, meninges, pia mater cells, arachnoid membrane cells, dura membrane cells, cells lining a joint or brain or spinal cord parenchymal cells.


Fig. 1

SP-PE35 activity Vs NK1 transfectant




A

SP-PE35 activity Vs NK2 transfectant



B

SP-PE35 activity Vs NK3 transfectant




C




Fig. 2

SP-PE treatment increases thermal latency




3/4

Figure 3



4/4

Figure 4



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/29064

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 C12N15/31 C07K7/06 C07K14/21 A61K47/48 A61K38/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K C07K C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, EMBL, MEDLINE		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MANTYH ET AL.: "Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor" SCIENCE, vol. 278, 10 October 1997 (1997-10-10), pages 275-279, XP002163145 cited in the application figures 3,4; table 1 <div style="text-align: center;">--- -/--</div>	1-19
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*G* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center;">19 March 2001</div>		Date of mailing of the international search report  <div style="text-align: center;">29/03/2001</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer  <div style="text-align: center;">van Klompenburg, W</div>

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/29064

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BUECHLER ET AL.: "Synthesis and characterization of a homogenous chemical conjugate between basic fibroblast growth factor and saporin"</p> <p>EUR. J. BIOCHEM., vol. 234, no. 3, 15 December 1995 (1995-12-15), pages 706-713, XP000990313 page 706 -page 708, left-hand column figures 4-8; table 2</p>	1-19
A	<p>WO 97 13410 A (FISHER CAROLINE E ;MURPHY JOHN R (US); LEEMAN SUSAN E (US); BOSTON) 17 April 1997 (1997-04-17) claims 1,3,16,27 page 3, line 14 -page 4, line 7</p>	1-19
A	<p>US 5 747 641 A (PABO CARL ET AL) 5 May 1998 (1998-05-05) column 3, line 51 - line 62 column 7, line 54 -column 8, line 3 column 13, line 22 - line 24 column 27, line 28 -column 56</p>	1-19

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/29064

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9713410 A	17-04-1997	AU 698031 B	22-10-1998
		AU 7595296 A	30-04-1997
US 5747641 A	05-05-1998	US 5674980 A	07-10-1997
		US 5804604 A	08-09-1998
		US 5670617 A	23-09-1997
		US 5652122 A	29-07-1997
		AT 142266 T	15-09-1996
		AU 658818 B	04-05-1995
		AU 7182991 A	24-07-1991
		CA 2071214 A	22-06-1991
		DE 69028412 D	10-10-1996
		DE 69028412 T	27-03-1997
		DK 506884 T	04-11-1996
		EP 0506884 A	07-10-1992
		ES 2091916 T	16-11-1996
		GR 3021474 T	31-01-1997
		WO 9109958 A	11-07-1991
		AT 173016 T	15-11-1998
		AU 667244 B	14-03-1996
		AU 5083293 A	15-03-1994
		CA 2135642 A	03-03-1994
		DE 69321962 D	10-12-1998
		DE 69321962 T	01-07-1999
		DE 656950 T	14-03-1996
		DK 656950 T	19-07-1999
		EP 0656950 A	14-06-1995
		EP 0903408 A	24-03-1999
		ES 2123062 T	01-01-1999
		FI 945248 A	05-01-1995
		JP 2869396 B	10-03-1999
		JP 10033186 A	10-02-1998
		JP 2702285 B	21-01-1998
		JP 7503617 T	20-04-1995
		KR 153027 B	15-10-1998
		NO 944273 A	17-02-1995
		NZ 255831 A	24-04-1997
		WO 9404686 A	03-03-1994

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**